JP2001276217A - Biocoated adsorbent for tissue, plasma or blood dialysis of patient having single disease or a plurality of diseases - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an adsorption material coated with a fixed monoclonal antibody against a tumor necrosis factor(TNF), or the like, which is utilized for the dialysis of blood, transport of plasma and dialysis of tissues. SOLUTION: The adsorption material contains TNF and anti-TNF or anti- TNF precursor protein or a TNF fragment or an anti-TNF fragment and a TNF transport protein further containing an antibody reacting with a pathogenic factor causing a disease, and the antibody is coated to be utilized for a columnar biosystem.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to tumor necrosis factor (T)
The present invention relates to the field of improved plasma export and dialysis obtained using adsorbents or columns coated with a plurality of antibodies with certain monoclonal antibodies against NF), its precursors, metabolites and transport proteins. TNFa is an acute or chronic disease, cancer, cardiovascular disease, pulmonary artery disease, liver disease,
Muscolusleletal disease, nervous system disease, kidney disease, otolaryngology system, eye system, skin disease,
It shows a very distinctive pattern in patients with rejection status after organ transplantation.

[0002]

[Prior art]Current technology and clinical practice  Therapeutic plasma export is available for patients with circulating virulence factors
Provide a well-known treatment in the presence of circulating pathogenic substances
Performed on patients (Sprenger, KBG: Franz, HE, Blut
reinigungsverfahren, Stuttgart 1985). Diseased tissue
In homoeostatic balance
Isolation of the above virulence factors results in IgM paraprotein blood
Illness, whole body erythematous lure and good pasture syndrome
Has shown good results in clinical conditions such as
Was. When all cellular components have been removed in advance,
Micropore membranes in the 3-4 dalton range are useful for plasma separation
It is effective. To guarantee the amount of protein in the blood,
It is important to reinject 5% human albumin.
The purpose of plasma export is autoantibodies, circulating immune complexes,
Pathogenicity such as paraproteins as well as cytoplasmic toxins
It consists in selectively eliminating factors.

[0003] Replacing 3-4 liters of plasma with a replacement solution causes a reduction in the amount of protein by 37%. By repeating this, 22%, 14%, 8
% Of its effect (Schroder, JO, Eul
er H. H: Plasmapharese beiAotoimmunerkrankungen, G
elbe Hefte 4/95). Within the next 24 hours, the amount of protein rapidly recovers to a level of up to 68.5% of the initial value. Furthermore, elimination of antibodies rapidly stimulates biosynthesis, with more than 68% of serum factors not surprising (Schroder,
JO, Euler H. H: Plasmapharese bei Aotoimmunerkran
kungen, GelbeHefte 4/95).

[0004] Thus, by providing a sorbent specifically coated with monoclonal antibodies, the disease-causing factors are selectively separated and all other plasma proteins are recycled. This means that replacement of important proteins is no longer necessary and is a more practical method for clinical use.

[0005] The symptoms of chronically ill patients are:
Significant changes in key factors in plasma and tissues can be confirmed by observing or measuring. For example, detailed research results can be found in chronic autoimmune diseases with inflammatory features such as rheumatoid arthritis. In the present application, cytokines, which are major mediators of both immunity and inflammation, are extremely prominent.

[0006] The network of pro- and anti-inflammatory cytokines is not significantly balanced in chronic diseases. That is, abnormal concentrations of interleukin 1 (IL-1) and tumor necrosis factor (TNF) α are biosynthesized in synovial fluid by macrophages, and interleukin 6 (IL-
6) and interferon alpha and other cell growth stimulating or inhibiting factors. As a result, another group of three cytokines with immunoregulatory, chemotactic and mitogenic potential in all chronic diseases are biologically active (Feldmann, M., Brennan, FM., Maini, R: Role of Cy
tokines in Rheumatoid Arthritis, Ann. Rev. Immun
l., 14, 1996).

[0007] Further major contributors that cause the hyperplasia of rheumatoid synovial fibroblasts are platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and transforming growth factor β (TGFβ). Different stages of the disease are characterized by altering the activity of the growth factors at different stages of the dominance of the disease.

[0008] Another important factor in this cascade immune response, which is a prerequisite for the overall process, is exhibited by marked changes in tumor necrosis factor a (TNF). Anti-tumor necrosis factor α (anti-TNFa) in rheumatoid disease
Clinical value represents further evidence of an effective treatment concept (Feldmann, M., Elliot, MJ., Woody, JN., Maine
i, R .: AntiTumor NecrossisFactor- a Therapy of Rh
eumatoid Arthritis, Adv. Immunol., 64, 1997). However, there are antibody responses to therapies that undermine the therapeutic effects of anti-TNFa.

However, long-term efficacy is achieved when TNFa is reduced by other techniques, such as an extracorporeal column system coated with a monoclonal TNFa antibody. By utilizing a dedicated column system coated with monoclonal antibodies, the plasma export technique can be used for several years without major complications or loss of clinical efficacy. Thus, similar procedures can be recommended for cancer, organ transplants with rejection, and other relapses or chronic diseases.

[0010]

SUMMARY OF THE INVENTION The present invention has been made in view of the above points, and can be used for hemodialysis, plasma export, tissue dialysis, and a plurality of monoclonal antibodies against tumor necrosis factor (TNF). It is an object of the present invention to provide an adsorbent or a column coated with an antibody.

[0011]

SUMMARY OF THE INVENTION The object of the present invention is to provide a TNF,
TNF further comprising an anti-TNF or anti-TNF precursor protein, or a TNF fragment or anti-TNF fragment, or an antibody reactive with a disease-causing pathogenic agent
This is achieved by an adsorbent used for a column-shaped biosystem coated with an antibody and comprising an antibody.

[0012]Results of previous research  Following EP 0 214 392 B1, membranes, chews
Transfer, made of tubes, catheters or plastic materials
Medical devices such as plants, coated metal and glass,
Attachment of pathogenic viruses, bacteria and fungi,
Provides attachment of products, toxins, lipoids and drugs, and is shared by antibodies.
This results in a covalently coated plastic surface.
The antibody is characteristic of an F (ab) 2-fragment and is homologous.
Log or monoclonal immunoglobulin class G1, G
2, G3 and / or G4 and / or IGM, IGE, IG
Specific antigen or pathogenic virus from D and / or IGA
Bacteria, fungi or pathogenic metabolites, toxins
Quite selective reaction with antigenic determinants from poids and drugs
Is induced by

[0013]Principle of adsorbent preparation  As mentioned above, the present invention relates to columns, biomaterials or
Available in tissue, blood or plasma dialysis in plant form
For the use of biocoated adsorbents
Provide a solution. Preferred effects of the treatment device are:
Pathogenic agents from plasma or diseased tissue without further damage
The particular exclusion of the child. For this type of plasma transfer
Reinfusion or replacement of essential plasma factors by
Is particularly effective.

In order to ensure the above, antibodies directed against TNF and / or TFN-metabolites and / or TNF-transport proteins and / or TNF fragments, and furthermore antibodies which are particularly reactive with the virulence factor of the disease to be treated It is important to have a biocoated adsorbent. Claims 1 to 163 reflect the subtle preparation of the biocoated adsorbent. Preferably, the biocoated adsorbent is defined as a column according to claims 150 to 159. Claims 160 to 163 indicate the main use of the column. The use of a biocoated adsorbent and a column in the extracorporeal system of the present invention is preferable for patients with acute or chronic diseases, cardiovascular diseases, pulmonary artery diseases and other diseases, cancer and patients with rejection after organ transplantation. Effective, improve the efficacy of extracorporeal systems.

The reduction of TNF in plasma and diseased tissues by using monoclonal antibody coated columns is
Runs for a long time without loss of efficacy. Therefore, there is an advantage that the medicine required for treating the disease is greatly reduced.

Acute or chronic disease and measurable TNF, anti-TNF, anti-TNF factor gene construct, TNF precursor, its protein, TNF binding protein in plasma or tissue, extracorporeal dialysis or plasma export as a medical product in patients The use of a column with TNF, anti-human TNF, anti-TNF gene, antibodies to its construct, anti-TNF precursor or anti-TNF
It is recommended to use antibodies to transport proteins or TNF transport protein antibodies as well as certain biocoatings of specific antibodies to disease.

The antibody is biocoated with TNF, anti-TNF, a TNF fragment, an anti-TNF fragment, and the adsorbent is passed from a patient through a column of the present invention containing additional antibodies specifically directed against virulence factors. Local perfusion of the blood continuously results in the covalent attachment of the virulence factor, with the elimination of the pathogenic derivative from the plasma.

[0018]

BEST MODE FOR CARRYING OUT THE INVENTIONExample of adsorbent preparation  In the normal procedure, the biocoated sorbent is
Used to coat plasma columns,
Ocoated sorbents are used for catheters, filters,
Also useful for other medical products such as plants, tubes, etc.
It is clear that we expect it to work.

The basic material of the adsorbent often consists of sepharose, cellulose, sepharose derivatives, agar, or agar aggregates with or without end groups prepared for covalent attachment.

Polyolefin, polyester, polyether, polyimide, polyurethane, polyvinyl chloride, polystyrol, polysulfone, polyacryl, polymethacryl, polypropylene, polyvinylpyrrolidone, fluorine-containing polymer, derivatives of the above compounds,
It is preferable to use a mixture thereof, a copolymer thereof, a silicon-containing polymer, or the like. The plastic material is of polar quality and it is possible to change the polarity by a chemical reaction.

The immobilization of the antibody on the adsorbent is performed by using bromocyan,
It is usually improved by thiophosgene and thionyl chloride. As a result of the above technique, the antibody is adsorbed or covalently bound to the surface of the adsorbent, and the F
Preferably, c, F (ab) 2 or Fab fragments are adsorbed or covalently bound. The ratio of the antibody coated on the adsorbent material is 1 to 95% of the antibody against TNF, anti-TNF, anti-TNF factor gene construct, its precursor, its protein, and TNF binding protein.
In the range of weight percent, less than 100 weight percent is introduced by additional antibodies reactive with the particular pathogenic antigen.

Other suitable products comprise 100% by weight of antibody to TNF, or 1 to 95% of antibody to TNF.
% By weight, less than 100% being refilled by additional antibodies reactive with the pathogenic antigen.

[0023]Clinical application of sorbent  Coated with adsorbent and antibody for hemodialysis or plasma transport
The use of a column packed with an adsorbent material is a feature of the present invention.
Is the advantage. In clinical practice, products consisting of the above materials
Of monoclonal antibodies in tissues, tissues and cell cultures
And the antigen and / or antibody is adsorbent and / or extracorporeal column
Specific pathogens in biological fluids used in the system
Original, growth factor, specific protein or peptide, specific
Toxin, specific enzyme, specific hormone, specific receptor, specific
Represents cell or tissue markers, specific cytokines
Use for all diseases with a clear pathogen.

Furthermore, clinical practice refers to specific pathogenic antigens, growth factors, specific proteins or peptides, specific toxins, specific enzymes, specific hormones, specific receptors, specific cells or tissue markers, specific cytokines in biological fluids. Use the medical product in all diseases that have no, but clear pathogens, but different antigens or antibodies are directly or indirectly correlated with the disease, monoclonal antibodies are generated and the antigen and / or antibody Is used to coat the sorbent and / or extracorporeal column system.

[0025] In addition, in clinical practice, all diseases with a distinct immunopathogen representing a specific pathogenic antigen or antibody utilized to generate monoclonal antibodies to coat the sorbent and / or extracorporeal column system are used. And use the medical product.

Further, in clinical practice, the invention describes the properties of a particular pathogenic antigen or antibody used to generate monoclonal antibodies for coating adsorbents and / or extracorporeal column systems. The medical product is used in all illnesses that have a clear pathogen other than the mentioned or isolated material.

[0027]Normal preparation of adsorbent  The technology for coating an antibody with an adsorptive material is described in European Patent No. 0
No. 214392B1.
The procedure of antibody coated on plastic material is γ-ray treatment,
Ionic or ozone corrosion, up to pH 7.5 or 1
Other pre-treatments and adsorptions up to 0.5
Acrolein that promotes the immobilization of antibodies on the surface of the drug
Done. Similar results were obtained with the alkylating agent iodide
Obtained by pre-treating the surface with chill
You.

The combined pretreatment of the adsorbent surface is utilized in combination with the above method and contact enhancement with bromocyan, thiophosgene or thionyl chloride, thus improving the covalent affinity of the medical product of the present invention. You.

Another method of coating the antibody is to treat the pretreated adsorbent material with a saturated solution of the antibody for 1 to 10 days.
Incubate at 20-40 ° C. for hours.

After the antibody coating by the above method, the adsorbent material was washed with a phosphate buffer to remove excess antibody, and then the material was dried for 8 to 24 hours and filled under aseptic conditions.

Experimental Results for THF-Adsorbents There are a variety of experimental models and clinical conditions that investigated columns coated with monoclonal antibodies.

In Table 1, dogs with chronic pyelonephritis following side effect antibiotics developed increased TNF levels, which levels were significantly reduced by plasma export using anti-TNF monoclonal antibody coated on the column. did. Anti-TNF plasma export was performed every other day for 4 hours. After 35 days, the tissues of the treated and control dogs were examined while monitoring for signs of inflammation. The treatment improved both parameters.

[0033]Table 1  Treatment of pyelonephritis by AB-TNFa-plasma export  (Day) TNFa (plasma) (μg) urine culture (C / ml) Tissue (T / K) (T / K) (path. T / K) 10, 20 +/- 0,050, 18 +/- 0,04 10^Five/Ten^Five -/-10 0,36 +/- 0,06 0,32 +/- 0,05 10^Five/Ten⁶ ++ / ++ 21 0,45 +/- 0,05 0,43 +/- 0,06 10⁶ Ten⁷ ++++ / ++++ 35 0,25 +/- 0,06 0,52 +/- 0,06 10^Four Ten⁷ ++ / ++++ 49 0,26-/ + 0,05 0,56 +/- 0.05 10^Three Ten⁶ ++ / +++++Treatment of pyelonephritis by AB-TNFa- / protein-A-plasma export  (Day) TNFa (plasma) (μg) urine culture (C / ml) Tissue (T / K) (T / K) (path. T / K) 10, 18 +/- 0,07, 19 +/- 0,04 10^Five/Ten^Five + / + 10 0,39 +/- 0,06 0,36 +/- 0,07 10^Five/Ten⁵ ++ / ++ 21 0,55 +/- 0,05 0,53 +/- 0,06 10⁶ Ten⁶ ++++ / ++++ 35 0,22 +/- 0,06 0,52 +/- 0,06 10^Four Ten⁷ ++ / ++++ 49 0,26-/ + 0,05 0,56 +/- 0.05 10² Ten⁶ ++ / +++++ Experiment 1: Inoculation of pyelonephritis is better with low dose antibiotics
Transformed into pyelonephritis and increased TNFa levels
Show. Chronic disease is shown in the untreated group (K). The dog is Ann
Treatment started on day 21 with TNF adsorbent
(T). TNFa treatment shows distinctly different therapeutic effects
You. Tissue discovered by lymphocyte infiltration is treated with anti-TNF
Clearly reduced. Experiment 2: Treatment with the addition of anti-protein-A-factor
The effect has been improved. C is a colony.

In Table 2, dogs drinking 5% dextran sulfate in drinking water for 6 consecutive days show signs of colitis with elevated TNFa levels. further,
In the present application, the amount of TNFa was obviously reduced and improved at the same time by the plasma transport by the adsorbent coated with anti-TNFa. In the present virulence model, the column coated with anti-TNF and anti-protein A further improved the results of plasma export.

[0035]Table 2  Treatment of colitis by AB-TNFa-plasma export  (Day) TNFa (plasma) Diarrhea (pathogen) Tissue (T / K) (T / K) (path (path.) T / K) 10 0,20 +/- 0,05 0,17 +/- 0, 04 + / 0 + / + 15 0,37 +/- 0,05 0,35 +/- 0,06 +++ / +++ +++ / +++ 31 0,28 +/- 0,05 0,46 +/- 0,06 + / +++ ++ / ++++Treatment of colitis by AB-TNFa / protein-A-plasma export  (Day) TNFa (plasma) Diarrhea (pathogen) Tissue (T / K) (T / K) (path (path.) T / K) 10 0,18 +/- 0,07 0,19 +/- 0, 04 + / + + / + 15 0,43 +/- 0,06 0,46 +/- 0,07 +++ / +++ +++ / +++ 31 0,20 +/- 0,05 0,53 +/- 0,06 + / +++ ++ / ++++ Experiment 1: Colitis for 6 days with 5% dextrans in drinking water
Induced by adding to rufate, the chronic disease
Observed in control group (K). Serum TNF
Levels increased, and treatment with anti-TNF
The number of times has been reduced, and the discovered tissue has been significantly improved
(T). Experiment 2: Chronic colitis is anti-protein A factor
To the anti-TNFa coated column system
It was improved by

[0036]Clinical results of TNF-adsorbent  In Table 3, methotrexate / cortisol and elevated T
Rheumatoid arthritis resistant to treatment at NFa levels
One patient was treated by plasma export for 12 weeks. Clinically
Showed a clear improvement in mobility,
TNFa levels appeared to be reduced and the combined antibody
With anti-TNFa and anti-protein A / anti-β
When used as a coated column using Streptococcus-A
In addition, it is possible to increase the response speed of the patient.
Was. Serum TNFa levels are clearly reduced and overall migration
Sex seemed to have improved.

[0037]Table 3  Treatment of rheumatoid arthritis with AB-TNFa-plasma export  (Day) TNFa (plasma) (μg) Response speed CRP (P / K) (% P / K) (% decrease-P / K) 10 0,456 +/- 0,054 0,348 +/- 0,044 0/0 5/4 14 0,332 +/- 0,062 0,342 +/- 0,053 35/8 34/0 42 0,226 +/- 0,053 0,343 +/- 0,063 48/10 46/0 56 0,222 +/- 0,063 0,352 +/- 0,063 54/9 47/1 84 0,180-/ + 0,053 0,346 +/- 0,053 51/10 88/2AB-TNFa- / protein-A / β-streptococcus-A-by plasma export  Treatment of rheumatoid arthritis  (Day) TNFa (plasma) (μg) Response rate CRP (P / K) (% P / K) (% decrease-P / K) 10 0.518 +/- 0,075 0,619 +/- 0,046 0/0 0/0 14 0,339 +/- 0,064 0,636 +/- 0,076 37/6 34/0 42 0,335 +/- 0,053 0,653 +/- 0,066 39/4 43/7 56 0,212 +/- 0,064 0,552 +/- 0,064 54/9 65/16 84 0,096-/ + 0,054 0,526 +/- 0,053 59/11 87/18 with methotrexate / cortisol, the usual treatment
Patients with RA have progressed to TNFa plasmapheresis
Showed sexual illness. Confirm plasma TNF and CRP levels
Therefore, clinical success was determined using response speed criteria. second
In the treatment line, the column biosystem is TNF / β
-Coated several times with antibodies to Streptococcus haemolyticus. Coming
The floor results were even more favorable. Number of samples n = 7 patients CRP = C-reactive protein P = treated patients k = untreated patients.

In Table 4, multiple sclerosis patients analyzed from pathogenic liquid aspirates were treated by the above-described programmed plasma expulsion with an anti-TNFa extracorporeal system. The clinical pattern clearly showed the patient's improved condition.

In addition, the multi-coated column system with anti-TNFa and anti-protein A / β-macroglobin antibody showed good clinical results and prevented disease progression.

[0040]Table 4  Treatment of multiple sclerosis by AB-TNFa-plasma export  (Day) TNFa (plasma) (μg) Response speed CRP (P / K) (% P / K) (% decrease-P / K) 10 0,348 +/- 0,063 0,338 +/- 0,054 0/0 85/78 14 0,235 +/- 0,052 0,419 +/- 0,064 31/7 44/76 42 0,230 +/- 0,053 0,435 +/- 0,065 39/9 42/70 56 0,176 +/- 0,063 0,450 +/- 0,074 45/9 39/73 84 0,151-/ + 0,053 0,346 +/- 0,054 45/10 38/72AB-TNFa- / protein-A / β-2-microglobulin-plasma export  Treatment of multiple sclerosis  (Day) TNFa (plasma) (μg) Response speed CRP (P / K) (% P / K) (% decrease-P / K) 10 0,447 +/- 0,054 0,445 +/- 0,042 0/0 85/78 14 0,227 +/- 0,063 0,446 +/- 0,054 45/10 32/72 42 0,225 +/- 0,043 0,446 +/- 0,063 48/10 31/70 56 0,123 +/- 0,063 0,354 +/- 0,062 52/11 28/69 84 0,087-/ + 0,042 0,347 +/- 0,055 59/10 23/72 Patients with multiple symptoms of ongoing sclerosis should take all medications.
4 weeks after discontinuation, 3 weeks cycle, several weeks, TNFa
He was treated by plasma export. By interferon
Control groups receiving conventional treatment are in an advanced state
Was confirmed. Check plasma TNF and CRP levels,
The response speed is based on the mobility and the Karnofski index.
Using criteria for the subjective state of health
I did. In the second line of treatment, the column biosystem is T
Coated several times with antibody to NF / B-2M. Clinical
The results were more favorable. Number of samples n = 8 patients.

In Table 5, patients with progressive nephropathy (IGA, GN) and pathogenic urine analysis were treated with the anti-TNFa column method. Interestingly, the results of pathogenic urine showed that after 7 weeks of treatment, a concomitant decrease in serum levels of TNFa had improved to normal values. The use of a column coated with anti-TNF / anti-β-2-microglobulin resulted in the discovery of standardized urine and the method proved to be effective.

[0042]Table 5  Treatment of chronic glomerulitis with AB-TNFa-plasma export  (Day) TNFa (plasma) (μg) Response rate Proteinuria (P / K) (% P / K) (% decline-P / K) 10 0,75 +/- 0,043 0,86 +/- 0,032 0 / 0 5/8 14 0,58 +/- 0,034 0,74 +/- 0,032 33/7 34/6 42 0,52 +/- 0,024 0,64 +/- 0,022 39/9 46/7 56 0,48 +/- 0,022 0,71 +/- 0,034 41/9 49/7 84 0,36-/ + 0,015 0,65 +/- 0,035 41/10 54/7AB-TNFa- / A-β-2-microglobin-Chronic glomeruli by plasma export Flame treatment  (Day) TNFa (plasma) (μg) Response rate Proteinuria (P / K) (% P / K) (% decline-P / K) 10 75,0 / -0,035 0,85 +/- 0,045 0 / 0 5/8 14 0,71 +/- 0,035 0,76 +/- 0,037 44/9 42/7 42 0,55 +/- 0,031 0,75 +/- 0,027 48/10 46/7 56 0,52 +/- 0,022 0,67 +/- 0,035 57/11 58/9 84 0,42-/ + 0,022 0,75 +/- 0,041 59/10 58/7 All patients with chronic progressive glomerulonephritis Stop the medicine
4 weeks later, TNFa plasma export treatment in 3 weeks cycle
Received. Control group is recognized progress
Received conventional treatment with Immunorek.
I did. Check plasma TNF levels, change proteinuria,
The response speed is calculated using the standard
Had recovered to normal blood pressure. In the second line of treatment,
Iosystem has been tested several times with antibodies against TNF / B-2M.
Was The clinical results were more favorable. Inspection
Number n = 8 patients.

In Table 6, patients with chronic hepatitis B underwent plasmapheresis with a denatured column coated with anti-TNF or anti-TNF / HbsAg (hepatitis surface antigen). Clinically elevated TNF declined 12 weeks after treatment. Compared to anti-TNFa plasma export, column systems with dual coated antibodies proved to be more effective.

[0044]Table 6  Treatment of chronic hepatitis by AB-TNFa-plasma export  (Day) TNFa (plasma) (μg) Response speed Anti-Hbc, HbsAg (P / K) (% P / K) (% reduction-P / K) / 8 14 0,192 +/- 0,043 0,179 +/- 0,042 33/6 32/6 42 0,155 +/- 0,032 0,174 +/- 0,042 39/9 38/7 56 0,078 +/- 0,023 0,183 +/- 0,034 44/8 49/7 84 0,076-/ + 0,037 0,157 +/- 0,027 46/9 54/7Treatment of chronic hepatitis by AB-TNFa- / HbsAg-plasma export  (Day) TNFa (plasma) (μg) Response speed Anti-Hbc, HbsAg (P / K) (% P / K) (% reduction-P / K) 10 0,177 +/- 0,03 0,168 +/- 0,047 0 / 0 5/8 14 0,173 +/- 0,035 0,161 +/- 0,054 44/9 42/7 42 0,060 +/- 0,024 0,158 +/- 0,035 48/10 46/7 56 0,053 +/- 0,034 0,157 +/- 0,036 56 / 10 58/9 84 0,064-/ + 0,025 0,155 +/- 0,055 59/10 63/7 Patients with chronic progressive hepatitis,
Receiving TNFa plasma export treatment in 4-week, 3-week cycles
Was. The control group is in a known progress state
-Received conventional treatment with Feron. Crystal TNF level
The hepatitis serum profile and response speed
It is determined using the criteria for the awareness of
File recovered. In the second line of treatment, column bio
The system consists of hepatitis B surface antigen (HbsAg) and Hbc
(Hepatitis B core) coated several times. Coming
The floor results were more favorable. Number of samples n = 8 patients
Met.

In Table 7, patients exhibiting acute rejection after organ transplantation exhibited elevated TNF levels and anti-TNF levels.
a Received plasma export. A clinically significant improvement was achieved with multiple coated columns containing antibodies against human leukocyte antigen, OKT3 and anti-human leukocytes.

[0046]Table 7  Treatment of rejection after kidney transplantation with AB-TNFa-plasma export  (Days) TNFa (plasma) (μg) Response speed Creatinine 0 (P / K) (% P / K) (% reduction-P / K) 10 67 +/- 0,06 0 66 , 05 0/0 5/8 14 0,42 +/- 0,05 0,54 +/- 0,06 35/28 30/21 42 0,38 +/- 0,05 0,51 +/- 0 , 08 39/31 38/25 56 0,36 +/- 0,04 0,47 +/- 0,07 44/41 46/30 84 0,32-/ + 0,05 0,49 +/- 0 , 04 47/38 52/32AB-TNFa / HLA, OKT3 and leukocyte-plasma export after kidney transplantation  Treatment of rejection  (Day) TNFa (plasma) (μg) Response speed Creatinine I (P / K) (% P / K) (% reduction-P / K) 10 67 +/- 0,04 0 66 66 , 04 0/0 5/7 14 0,31 +/- 0,05 0,46 +/- 0,05 44/29 42/27 42 0,24 +/- 0,03 0,48 +/- 0 , 06 52/27 46/25 56 0,21 +/- 0,05 0,47 +/- 0,06 56/28 58/28 84 0,21-/ + 0,04 0,38 +/- 0 , 05 59/39 63/37 Patients with rejection after kidney transplantation
Treated. The control group is the recognized progress
State of cyclosporin / ganciclovi (ganciclovi)
r) / Methyl-prednisolone
Had received conventional treatment. Check plasma TNF levels and
Changes in Reatinin, Response Speed, Standards for Awareness of Health
The urine was recovered and normal proteinuria recovered. Second treatment
In the system, the column biosystem is HLA, OKT3
Antibodies and monoclonal antibodies against leukocytes
Coated several times. Clinical results are more favorable
Was. The number of samples was n = 5 patients.

In Table 8, patients with elevated TNFa plasma levels similar to chronic bronchitis and other chronic diseases were selected for extracorporeal anti-TNFa plasmapheresis. An acceptable rate of successful treatment was observed 8 weeks after treatment with the anti-TNF column method. Significant improvement was observed after 6 weeks of pathogen treatment. When a double-coated column consisting of anti-TNF and anti-cold agglutinin was used, respiratory capacity was clearly improved, and the improvement was observed about 4 weeks after the start of treatment.

[0048]Table 8  Treatment of chronic bronchitis by AB-TNFa-plasma export  (Days) TNFa (plasma) (μg) Response rate Proteinuria (P / K) (% P / K) (% decrease-P / K) 10 0,295 +/- 0,043 0,86 +/- 0,032 0/0 5 / 8 14 0,278 +/- 0,034 0,178 +/- 0,032 33/7 34/6 42 0,262 +/- 0,024 0,162 +/- 0,022 39/9 42/7 56 0,158 +/- 0,022 0,177 +/- 0,034 41/9 49/7 84 0,149-/ + 0,015 0,230 +/- 0,035 41/10 54/7Treatment of chronic bronchitis with AB-TNFa-cold agglutinin-plasma export  (Day) TNFa (plasma) (μg) Response rate Proteinuria (P / K) (% P / K) (% decrease-P / K) 10 0,175 +/- 0,035 0,185 +/- 0,045 0/0 5/8 14 0,178 +/- 0,035 0,186 +/- 0,034 44/9 42/7 42 0,135 +/- 0,031 0,175 +/- 0,027 48/10 46/7 56 0,097 +/- 0,022 0,142 +/- 0,032 57/11 58 / 9 84 0,082-/ + 0,022 0,152 +/- 0,041 59/10 58/7 Patients with symptoms of chronic bronchitis,
Receiving TNFa plasma efflux treatment in 2-week and 3-week cycles
Was. The control group is a recognized progressive state,
Received conventional treatment with antibiotics / cortiazole. blood
Plasma TNF levels were confirmed and pulmonary artery function was confirmed. response
Velocity was determined using improved motion criteria. Second treatment
For strains, the column system is gegen TNF / cold
Coated several times with antibody to cold agglutinin. Clinical results are good
More favorable results were obtained. The number of samples was n = 8 patients.

[0049]Properties of practical biocoated adsorbents  The biocoated adsorbent material of the present invention can be used for TNF,
TNF, anti-TNF factor gene construct, TNF precursor
Body, protein, TNF binding protein, TNF or
Consisting of antibodies to fragments of TNF
It also consists of antibodies to the substance.

-Staphylococcus aureus, mitis staphylococci, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Streptomyces, Staphylococcus pyogenses and viridans, Neisseria cateralis, E. coli, β
Mixture of hemolytic Streptococcus, hepatitis A antigen, Hbs antigen, and lipopolysaccharide bacteria / virus.

-Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus spirogen and Viridan, Neisseria catellaris, Escherichia coli, β-hemolytic streptococci, and lipopolysaccharide Bacteria / virus mixture.

-Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, staphylococci, staphylococcus spirogens and viridans, Neisseria catellaris, Escherichia coli, beta-hemolytic streptococci, Ribosomal proteins from antibodies to hepatitis A antigen, Hbs antigen.

Ribosomal proteins from Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus spirogen and Viridan, Neisseria cateralis, Escherichia coli, β-hemolytic streptococci .

Β-hemolytic streptococcus A or viral capsid.

Polysaccharides from pneumococcal or viral capsids.

Anti-I-cold agglutinin, polypolysaccharides from pneumococci and against viral capsids, chlamydia and mycoplasma.

Polysaccharides from pneumococci and against influenza virus, influenza, hemagglutinin, peptides and against hemagglutinin.

Polysaccharides from pneumococci, against influenza virus, influenza hemagglutinin peptides and against anti-I-cold agglutinin.

-Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and odorous bacterium,
Staphylococcus spirogen and Viridan, Neisseria catellaris, E. coli, β-hemolytic streptococcus A, hepatitis A antigen, Hbs antigen and influenza virus, influenza hemagglutinin peptide as well as protein A
Bacterial / viral mixture consisting of antibodies to

Against hepatitis A antigens and viral capsids.

Against hepatitis B antigen (Hbs) or hepatitis B antigen (Hbs) nuclear fragments (DNA) and viral capsids.

For hepatitis B antigen (Hbs) and transactivator Hbx protein.

Hepatitis C virus genome (nucleocapsid protein).

Reverse transcriptase and against hepatitis C antigen, protein A, herpes simplex, influenza and influenza hemagglutinin peptides.

-Β hemolytic streptococcus A, endothelin (en
dothelin) (VEGF), a fragment of endothelin (VEG)
F fragment), endothelin-receptor-antagonist, VCAM, protein A, conductin-Protein, SDF-1-protein, 6
-C-Kine protein and MIP-3β-protein.

-Β hemolytic streptococci, protein A, P-
Glycoproteins and lipids.

HLA-DR 1,2,4, endothelin (VEGF), a fragment of endothelin (VEGF fragment), an endothelin-receptor-antagonist (V
EGF-receptor-antagonist), VCAM, protein A, conductin protein, SDF-1-protein, 6-C-kine-protein and MIP-3
β-protein.

-For HLA-DR 1,2,4, for viral capsid and for oligodendrocyte glycoprotein Typ (MOG).

For HLA-DR 1,2,4, for oligodendrocyte glycoprotein (MOG) and for Epstein-Barr virus (EBV).

For acetylcholine or acetyl receptor or fragments thereof.

Immunogenetic thyreoiditis (thyr
eoiditis) and acetylcholine.

Against β-hemolytic streptococci, influenza virus, influenza hemagglutinin peptide and lipopolysaccharide (LPS) and chaperoni
For n).

Against β-hemolytic streptococci, fan-glycopeptides, influenza virus, influenza hemagglutinin peptides, against lipopolysaccharides on matrix-protein and β-2-microglobulin.

-Creatine, urine, uric acid, lipids-Cocksakie virus, viral capsid and van-glycoprotein.

-Herpes simplex, influenza virus, influenza hemagglutinin peptide, giant cell virus, protein A, glycoproteins for lipids.

-CD20B cells-lymphocytes, epithelial specific antigen (ESA), anti-human episialin (Episialin,
EMA), farnesyl-transferase, cyclin-dependent kinase, E1-A-protein,
ATM, MLH-1, XP-A, XP-B, MGMT,
For BLM, NF1, PTH, p27, RB and for caspase activator.

Against human reverse transcriptase and CD20B cell lymphocytes;

-CD5 and CD72B cell lymphocytes.

For human reverse transcriptase, for B cells lymphocytes CD5 and CD72, epithelial specific antigen (ESA), anti-human episialin (EMA), farnesyl-transferase, cyclin dependent kinase, E1-A Protein, ATM, MLH-1, X
PA, XP-B, MGMT, BLM, NF1, PT
For H, p27, RB and caspase activator.

CD2, CD3 and C of B cell lymphocytes
D20.

Human reverse transcriptase, CD2, CD3, CD
5, for CD7 and for T lymphocytes.

-Monoclonal CD against T lymphocytes
2, CD3, CD5 and CD7, epithelial specific antigen (ES
A), anti-human episialin (EMA), farnesyl-transferase, cyclin-dependent kinase, E
1-A-protein, ATM, MLH-1, XP-A,
XP-B, MGMT, BLM, NF1, PTH, p2
7, for RB and for caspase activator.

Human reverse transcriptase and CD of T lymphocytes
2, against CD3, CD5 and CD7, against epithelial specific antigen (ESA).

CD13, CD1 on myeloid leukemia cells
4, CD15, CD33, CD34.

Human reverse transcriptase and CD13, CD14, CD15, CD33, CD34,
Epithelial specific antigen (ESA), anti-human episialin (E
MA), farnesyl-transferase, cyclin dependent kinase, E1-A-protein, ATM, ML
H-1, XP-A, XP-B, MGMT, BLM, NF
1, for PTH, p27, RB and for caspases.

Human reverse transcriptase and HLA-DR, HL
For AB3503 and CD34 antibodies.

Human reverse transcriptase, CD of T cell lymphocytes
5 and against epithelial specific antigen (ESA).

For human reverse transcriptase and PG-M3 promyelocytic cells (Moab) and for retonoid acid-receptor α.

For human reverse transcriptase and Mab-macrophage cells, as well as epithelial specific antigen (ESA), anti-human episialin (EMA), farnesyl-transferase, cyclin dependent kinase, E1-A-protein, ATM, MLH-1, XP-A, XP-B,
For MGMT, BLM, NF1, PTH, p27, RB and for caspases.

Human reverse transcriptase, protein A, conductin protein, SDF-1-protein, 6-kine-protein, MIP-3β-protein and VCA
For M.

Reverse transcriptase, P-glycoprotein (M
DR) and P-glycoprotein (MDR) fragment.

Reverse transcriptase, vascular-endothelial growth factor (VE
GF), fragments of vascular-endothelial growth factor (VEGF) and V
EGF-receptor-antagonist.

An epithelial specific antigen (ESA), against matrix metalloproteinase-2 (MMP-2) and / or matrix metalloproteinase-1 (MT
1-MMP) activator.

Immunogenetic therapy in antisense therapy or from gene therapy, from gene transfer therapy, from viral vector gene therapy, from viral vector augmentation therapy, from artificial chromosome therapy, from DNA plasmids Oligonucleotides for use in antibodies to an antigen from a tumor suppressor-oncogene-apoptosis-therapeutic, from a recombinant therapy or from a monoclonal or polyclonal antibody against the aforementioned antigens.

Reverse transcriptase, P-glycoprotein, H
ER2 / for new protein, for anti-human episialin (EMA) and for VCAM.

Reverse transcriptase, protein HER-2 / new protein, MYC, ERBB1-3, RAS, MSH
2, p53 and VCAM.

Reverse transcriptase, HER-2 / new protein, MYC, ERBB1-3, RAS, MSH2, p5
3 and against muteins caused by cancer growth, such as VCAM.

Reverse transcriptase, RAS, MSH2, p53
And muteins produced by cancer growth, such as VCAM.

Against vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, matrix proteins, catenin (catenin, α, β), neuronal adhesion proteins and cadherin thing.

Against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF), VEGF-receptor-antagonist, VCAM and HLA;
And human leukocytes.

-Against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF), VEGF-receptor-antagonist, VCAM, HLA and / or against human leukocytes and / or T lymphocytes.

-For VCAM protein and / or glycate product receptors, and / or
Or against Hemozoin.

-Plasmic reticulum falciparum
For the soluble form of the antigen, for the VCAM protein, for the glycate product receptor and for hemozoin.

A soluble form of the plasmaplasmic falciparum antigen,
For VCAM and ICAM proteins, for the receptor for glycate products and for hemozoin.

A soluble form of the plasmaplasmic falciparum antigen,
Or the glycosylphosphatidyl-inositol product from the plasma endoplasmic reticulum falciparum (glykosylphosphatidyl-i
nositol, GPI), trypanosome brucei (bruce
i) or for Mexican leishmania, or for VCAM and ICAM proteins, for the receptor for glycate products, or for hemozoin.

A soluble form of the plasmaplasmic falciparum antigen,
Or glycosyl phosphatidyl-inositol product (GPI) from the endoplasmic reticulum falciparum, trypanosoma brucei or Mexican leishmania, or VC
For AM and ICAM proteins, for glycate product receptors, or for hemozoin, and for lipopolysaccharide.

For hemozoin, and for the endothelial receptor type PECAM-1 / CD31.

-Mycobacterium leprae, Mitsuda antigen, Damendula antigen.

Against VCAM and ICAM proteins, as well as leprosy, Mitsuda antigens and Damendula antigens.

-Protein A, protein p59Fyn-
Kinase.

Human reverse transcriptase, protein A, protein p59Fyn, activator protein-1 (AP
-1).

Human reverse transcriptase, protein A, protein p59Fyn, activator protein-1 (AP
-1) against serum amyloid A protein (SAA).

Human reverse transcriptase, protein A, protein p59Fyn, activator protein-1 (AP
-1), serum amyloid A protein (S
AA), plasminogen-activator-inhibitor-type-1 antigen (PAI-1), as well as farnesyl-transferase, cyclin-dependent kinase and caspase activator.

Human reverse transcriptase, protein-1 (AP
-1), serum β-amyloid protein, β-amyloid protein fragment, β-amyloid precursor protein (βAPP), oncostatin M protein (Oncostat
in, OSM).

Human reverse transcriptase, mutant p53 protein, and Ki. Farnesyl-transferase, cyclin-dependent kinase and caspase activator, as well as for the 67 antigen.

Protein induced using human reverse transcriptase, mutated p53 protein and cholesterol-liposome gene transferred to tumor.

Conductin and P-selectin as well as reverse transcriptase, mutant p53 protein, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists.

Monoclonal farnesyl, as well as human reverse transcriptase, β-2 microglobulin (B2-MG), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists; Transferase, cyclin dependent kinase and caspase activator.

-Β-2 microglobulin (B2-M
G) vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, as well as monoclonal farnesyl-
Transferase, cyclin dependent kinase and caspase activator.

Against vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, oncostatin-protein and interleukin-6.

Human reverse transcriptase, receptor antigen CD4
And for the p24 antigen.

Against human reverse transcriptase, monoclonal receptor antigen CD4 and HIV-protease inhibitors.

-Mycobacterium, Mycobacterium tuberculosis, BCG antigen.

M. tuberculosis and BCG antigens.

M. tuberculosis, BCG antigen, vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, VC
For AM, telomerase, as well as farnesyl-transferase, cyclin-dependent kinase and caspase activator.

Vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, VCAM, HLA, human leukocytes,
For T lymphocytes and P-selectin.

HLA, against human leukocytes, T-
For lymphocytes, extracellular matrix and for P-selectin.

-Eosinophil cationic protein (EC
P).

Human reverse transcriptase, mutated p53 protein and against Epstein-Barr virus and against E1A virus protein.

Vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, VCAM and HL of the alpha domain
For AB-7 residue 75-84, for human leukocytes, for T lymphocytes and P-selectin.

Vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, VCAM and HL of the α domain
For AB-7 residue 75-84.

Vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists, VCAM and A-β-2-M-
For amyloid.

Vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists, VCAM and A-β-2-M-
Amyloid, Conductin-protein, SDF-1-
Protein, 6-C-kine-protein and MIP-
3-β-protein.

A-β-2-M-amyloid-selectin (P, L), against CD994, NKG2ABCL2 and vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists .

Ammonium bile acid and bilirubin.

CD3, LAF, A-β-2-M-amyloid-selectin (P, L), CD994, NKG2
ABCL2, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists.

CD994, NKG2A, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists.

-CD3 and LAF-1-α.

MDR-1-protein type MRK1
6 and C219, with vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, protein A and P-selectin or polyclonal antibodies against the aforementioned antigens.

MDR-1-protein type MRK1
6 and C219, vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, vascular endothelial growth factor (VEGF),
Fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonist proteins.

A fusion protein between the Fab fragment from the monoclonal antibody (C215) and SEA (Staphylococcal enterotoxin antigen) and vascular endothelial growth factor (V
EGF), vascular endothelial growth factor (VEGF)
And VEGF-receptor-antagonists.

Vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, against farnesyl-transferase, cyclin-dependent kinases and caspase activators and selectins (P, L).

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor-antagonists, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonist proteins, selectins (P, L), interleukin-6 For Leukin gene expression constructs.

-Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) fragment and VEGF-receptor-antagonist, vascular endothelial growth factor (VEGF), fragment of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonist protein, selectin (P,
L) and OX40.

HLAB3503 or fragments or superantigens or their receptors.

Interleukin 8 or fragments or superantigens or their receptors; epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists; Selectin (P, L) and interleukin-1.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor-antagonists, selectin (P, L) and interleukin-2 receptor.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) fragments and VEGF-receptor-antagonists, selectin (P, L) and squamous cell carcinoma-antigen (SC
C).

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragment and VEGF-receptor-antagonist, selectin (P, L) and matrix-protein-tenascin-C (TN-C).

-Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragment and against VEGF-receptor antagonists, selectin (P, L) and sialyl Lewis x.

-Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and against VEGF-receptor antagonists, selectins (P, L) and IGM-cytostatic compounds.

Protein A, against human HLA class I antigen, antithrombopoietin
oetin), for liposaccharide and fanglycoprotein.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor-antagonists, selectin (P, L) and NF-kapp-B-gene expression constructs.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor antagonists, selectin (P, L) and endothelial activating polypeptide II (EMAPII).

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and against the VEGF-receptor antagonist, selectin (P, L) and anti-endothelial activating polypeptide II (EMAPII).

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor antagonists, selectin (P, L), anti-CD3 and glycoprotein EGP2 as a bispecific antibody.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) fragment and VEGF-receptor antagonist, selectin (P, L) macrophage-migration-inhibiting factor (MIF) and its antibody (anti-MI
F), Protein A, Conductin-protein, SD
F-1-protein, 6-C-kine-protein and MIP-3-β.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) and a VEGF-receptor antagonist, selectin (P, L), and a leukemia inhibitor (LI)
F) and against its antibody (anti-LIF).

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) and a VEGF-receptor-antagonist, selectin (P, L), and an antiram
p) For the gene construct.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor-antagonists, selectins (P, L), substance P (SP) and their substance P fragments.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor antagonists, selectins (P, L) and interleukin-1-
Receptor.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragments and VEGF-receptor antagonists, selectins (P, L), interleukin-2 and interleukin-4.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) fragments and VEGF-receptor-antagonists, selectin (P, L), substance P (SP) and vasoactive intestinal peptide (VIP), protein A,
Conductin-protein, SDF-1-protein,
6-C-kine-protein, MIP-3-β.

Epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, farnesyl-transferase, cyclin-dependent kinase And Proleration.

Reverse transcriptase, protein Her-2 due to cancer growth mutations / new, MYC, ERBB1-3, RA
S, against p53, against VCAM, against epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists .

-P-glycoprotein and p-glycoprotein fragments, endorphin, encephalin
lin), MSH, opioids, substance P, and their peptides, receptor antagonists and antagonists.

CD4, MHCII (major histocompatibility complex) -peptide complex and against LFA-1 (an antigen associated with leukocyte function). -A soluble form of the endoplasmic reticulum falciparum antigen, for the receptor of the VACM-protein and / or glycate-product, and / or for cp26 and cp29, circumsporozoit-protein and / or hemizoin of the endoplasmic reticulum falciparum.
(hemizoin).

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) fragments and VEGF-receptor antagonists, selectins (P, L), endothelial activating polypeptide II
(EMAPII), protein A, conductin-protein, SDF-1-protein, 6-C-kine-protein and MIP-3β.

For CD4 and MHCII (major histocompatibility complex) -peptide complex.

CD8 and MHCII (major histocompatibility complex) -peptide complex.

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) Fragment and VEGF-receptor antagonist, selectin (P, L), and neuropilin and endothelial proliferation as specific inhibitors of neovascularization.

HLA-Dr1,2,4, against oligodendrocyte glycoprotein, semaphorin as monoclonal type (MOG) antibody
For n).

HLA-Dr1,2,4, for oligodendrocyte glycoprotein (MOG), for Epstein-Barr virus, for semaphorin-protein.

Protein Her by cancer growth mutation
-2 / New, BRCA1, BRCA2, RAS, MSH
2, reverse transcriptase, farnesyl-transferase, cyclin dependent kinase and / or VC for p53
AM, monoclonal epidermal growth factor (EGFR),
Vascular endothelial growth factor (VEGF), vascular endothelial growth factor (V
EGF) fragment and VEGF-receptor-antagonist, selectin (P, L).

-Cancer growth blocking factor protein He
r-2 / new, BRCA1, BRCA2, RAS, MSH
2, reverse transcriptase, farnesyl-transferase, cyclin dependent kinase and / or VC for p53
AM, monoclonal epidermal growth factor (EGFR),
Vascular endothelial growth factor (VEGF), vascular endothelial growth factor (V
EGF) fragment and VEGF-receptor-antagonist, selectin (P, L).

-Oncoprotein Her-2 / New, BRCA
1, reverse transcriptase for BRCA2, RAS, MSH2, p53, farnesyl-transferase, cyclin dependent kinase and / or VCAM, monoclonal epidermal growth factor (EGFR), vascular endothelial growth factor (V
EGF), fragments of vascular endothelial growth factor (VEGF) and V
EGF-receptor-antagonist, selectin (P, L).

Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) a fragment of VEGF-receptor-antagonist, selectin (P, L) and an endothelial activating polypeptide
II (EMAPII), Conductin-protein, SDF
-1-protein and 6-C-kine-protein.

Reverse transcriptase, a protein Her-2 by cancer growth mutation / new, BRCA1, BRCA2, RA
For S, MSH-2, p53, farnesyl-
Transferase, cyclin dependent kinase and / or VCAM, epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists, monoclonal E1-A-protein.

For CD4, CD8, MHCII (major histocompatibility complex) -peptide complex, MH
CII (major histocompatibility complex)-peptide complex-
For I-peptide conjugates and peptidyl caspase inhibitors.

Protein Her by cancer growth mutation
-2 / New, BRCA1, BRCA2, RAS, MSH,
Reverse transcriptase, farnesyl-transferase, cyclin dependent kinase and / or VCA for p53
M, monoclonal epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and for VEGF-receptor-antagonists, selectins (P, L), E1-A-proteins and monoclonal caspase activators.

For HLA-DR1,2,4,
Against oligodendrocyte glycoprotein (MOG), against Epstein-Barr virus (EBV), polypeptide neurotoxin, against semaphorin protein as a monoclonal antibody.

HLA-DR1,2,4, against oligodendrocyte glycoprotein (MOG), against Epstein-Barr virus (EBV), microtubulin-related protein (MAPe),
For MAPs, Tau-protein, Semaphorin protein as monoclonal antibody.

CD4, against MHCII (major histocompatibility complex) -peptide complex, LFA-1
(Leukocyte function-related protein), HIV-
For proteinase-inhibitors.

CD4, MHCII (major histocompatibility complex) -peptide complex, against LFA-1 (leukocyte function-related protein), against HIV-proteinase inhibitor, against integrin, viral capsid, glycopeptide .

CD4, MHCII (major histocompatibility complex) -peptide complex, LFA-1 (leukocyte function-related protein), genogen HIV-proteinase-inhibitor, integrin and viral capsid, glycopeptide.

A cancer growth mutein Her against a reverse transcriptase as defined in claims 1-140.
2 / New, BRCA1, BRCA2, RAS, MSH2,
p53, farnesyl-transferase, cyclin-dependent kinase and / or VCAM, epidermal growth factor (EGFR), E1-A-protein ATM, HLM
1, XP-A, XP-B, MGMT, BLM, NF1,
Biosorbed column biosystem sorbent with additional antibodies to monoclonal caspase activator against PTH, p27, RB.

Creatinine, urine, uric acid and lipids, β
-For microtubulin and amyloid.

Cholera toxin, Pseudomonas ergotoxin A, staphylococcal alpha-toxin and staphylococcal enterotoxins A and B.

Reverse transcriptase, cancer growth mutein Her-2 / new, epithelial specific antigen (ESA), RAS, M
SH2, p53, farnesyl-transferase,
Cyclin-dependent kinase and / or VCAM, epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEG)
F) Fragments and VEGF-receptor antagonists, selectins, E1-A-protein ATM, MLH
-1, XP-A, XP-B, MGMT, BLM, NF
1, for PTH, p27, RB, and for monoclonal caspase activator.

Reverse transcriptase, cancer growth mutein Her-2 / new, epithelial specific antigen (ESA), RAS, M
SH2, p53, farnesyl-transferase,
Cyclin-dependent kinase and / or VCAM, epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEG)
F) Fragments and VEGF-receptor antagonists, selectins, E1-A-protein ATM, MLH
-1, XP-A, XP-B, MGMT, BLM, NF
1, for PTH, p27, RB, and for monoclonal caspase activator, matrix metalloproteinase-2 (MMP-2) and
/ Or matrix metalloproteinase-1 (MT1
-MMP).

Reverse transcriptase, protein Her-2 /
New, epithelial specific antigen (ESA), RAS, MSH2, p5
3. Farnesyl-transferase, cyclin dependent kinase and / or VCAM, epidermal growth factor (E
GFR), selectin (P, L), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, selectins, E1-A-protein ATM, MLH-1, XP-
A, XP-B, MGMT, BLM, NF1, PTH, p
27, for RB, and for monoclonal caspase activator, for matrix metalloproteinase-2 (MMP-2) and / or for matrix metalloproteinase-1 (MT1-MMP).

HLA-DR1,2,4, against oligodendrocyte glycoprotein (MOG), not only against the nerve growth inhibitor type NI35 / 250, but also against neurotrophic stimulants and against semaphorin.

Growth factors such as angiogenin, chemokine, colony stimulating factor (CSF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), interferon (INF) , Interleukin (IL) keratinocyte growth factor (KGF), leptin (OB), leukemia inhibitory factor (LIF), nerve growth factor (NGF), oncostatin M (OSM), platelet-derived cell growth factor (PD- ECGF), pleiotropic stem cell growth (SCF),
Transforming growth factors a and b (TGF-a and TGF-
b).

Actin, cytokeratin, intermediate filaments, microtubulin, cell adhesion proteins, organelles, extracellular matrix, cell cycle
clus) effecting proteins, nuclear effecting proteins, receptor human cell antigens, hormones,
Reagents from signal transducer types, growth proteins, superantigens and oncogens, as well as their precursors, metabolites, prions, viroids, viruses, pro and eukaryotes, helminths, bacteria, protozoaes or fragments thereof And complexes.

Abbreviations MDR Protein resistant to multiple drugs 6-C-kine-protein Lymphocyte adhesion triggering chemokine (SLC) BCL2 Component of cell cycle, nucleus and growth metabolism Bilayer lipid membrane for BLM Ca ²⁺ BRCA1, 2 Components of cell cycle, nucleus and growth metabolism Caspase Components of cell cycle, nucleus and growth metabolism CD Surface antigen cluster of human leukocyte Chaperonin ATPase inhibitory protein Protein generated by heat and infection cp26 and cp29 locus Cyclin-dependent kinase Nuclear and Growth Metabolic Components Dystrophin A fusion protein, a single transducer (Dystrophin) protein in muscle E1A Cell cycle, nuclear and growth metabolic components Episialin (EMA) From epithelial tumors to large cell regression lymphoma Tampa Epithelial epithelial specific antigen Protein from epithelial tumor (small cell lung carcinoma cell line H69) ERBB1-3 Components of cell cycle, nucleus and growth metabolism / Oncogen FAS Components of cell cycle, nucleus and growth metabolism (Kern) antigen (core antigen DNA antigen) Hbs hepatitis B surface HBx hepatitis B transactivator protein HER-2 / new component of cell cycle, nucleus and growth metabolism / oncogen HLA-DR human leukocyte antigen class II antigen ICAM Cell Adhesion Protein KI67 Components of Cell Cycle, Nuclear and Growth Metabolism LAF Leukemia-related Factors Leukocyte Function Related to LFA Antigen LIF Leukemia Inhibitor Mdm2 Components of Cell Cycle, Nuclear and Growth Metabolism Resistance to Multiple Drugs of Type MRK16 and 219 Certain protein MDR1 protein MGMT Tilguanine-DNA methyltransferase NF1 Nuclear factor MIP-3β Macrophage inflammatory protein-3β MSH2 Melatonin stimulating hormone MYC Components of cell cycle, nucleus and growth metabolism NCAM surface receptor NKG2A Family of human natural killer cell receptor gene OX40 Oxidized low density protein p27 Components of the cell cycle, nuclear and growth metabolism p53 Components of the cell cycle, nuclear and growth metabolism PECAM-1 Receptors for platelets, endothelial and bone marrow cells, B and T lymphocytes P-glycoprotein Resistance to multiple drugs Protein p59Fyn cells Components of cycle, nucleus and growth metabolism Ramp-gene-construct Randomly amplified microsatellite polymorphism RB Components of cell cycle, nucleus and growth metabolism SDF-1 Stromal cell inducer Substance P Single transducer protein VCAM Vascular adhesion protein VEGF Vascular endothelial growth factor XP-A, XP-B Components of cell cycle, nucleus and growth metabolism

Continued on the front page F term (reference) 4C077 AA05 AA12 BB01 BB02 BB03 EE01 KK01 KK09 KK13 KK23 MM04 NN03 NN14 NN15 PP01 PP02 PP08 PP10 PP12 PP13 PP14 PP16 PP19 PP29 4G066 AA31D AC01B AC01C AC02B AC21C AC23 AC23 AC31C AD09C AD11C AD13C CA54 CA56 DA11 DA12 EA04

Claims (163)

[Claims] 1. TNF, anti-TNF or anti-TNF
Precursor protein, or TNF fragment or anti-TNF
An adsorbent for use in an antibody-coated columnar biosystem, comprising a fragment or a TNF transport protein further comprising an antibody reactive with a disease-causing pathogenic agent. 2. Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, pneumococci, Klebsiella pneumoniae, odorous bacteria, staphylococcus spirogen and viridan, Neisseria cateralis, Escherichia coli, β-hemolytic streptococcus, type A Hepatitis antigen, H
2. The biocoated columnar biosystem according to claim 1, further comprising an antibody against a bacterial / virus mixture of bs antigen and lipopolysaccharide (LPS), wherein the antibody is coated with a monoclonal or polyclonal antibody against the antigen. Sorbent. 3. Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, pneumococcus, Klebsiella pneumoniae, odor, staphylococcus spirogen and viridan, Neisseria cateralis, Escherichia coli, β-hemolytic streptococci, and lipo 3. The adsorbent for use in a biocoated columnar biosystem according to claim 1 or 2, further comprising an antibody against a polysaccharide bacterium / virus mixture, coated with a monoclonal or polyclonal antibody of said antigen. 4. Ribosomes from Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus spirogen and Viridan, Neisseria cateralis, Escherichia coli, β-hemolytic streptococci Hepatitis A antigen, Hb
The adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 3, further comprising an antibody against the s antigen, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 5. Ribosomes from Staphylococcus aureus, mild staphylococci, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus spirogen and Viridan, Neisseria catellaris, Escherichia coli, β-hemolytic streptococci The adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 4, further comprising an antibody against a protein, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 6. The biocoated column according to any one of claims 1 to 5, further comprising an antibody against β-hemolytic streptococcus A or a viral capsid, coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used for biosystems. 7. The biocoated column according to any one of claims 1 to 6, further comprising an antibody against a polysaccharide from pneumococcus or viral capsid, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used for biosystems. 8. An antibody against anti-I-cold agglutinin,
8. An antibody against polysaccharide from pneumococcus and an antibody against viral capsid, chlamydia and mycoplasma, coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the biocoated column-shaped biosystem according to any one of the above. 9. An antibody against a polysaccharide from pneumococcus, an antibody against an influenza virus, an influenza hemagglutinin peptide, and an antibody against a hemagglutinin, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used for the biocoated columnar biosystem according to any one of claims 1 to 8. 10. An antibody against a polysaccharide from pneumococcus, an antibody against influenza virus, an influenza hemagglutinin peptide, and an antibody against anti-I-cold agglutinin, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent for use in a biocoated columnar biosystem according to any one of claims 1 to 9. 11. Staphylococcus aureus, mild staphylococci,
Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and Streptomyces, Staphylococcus spirogen and Viridan, Neisseria catellaris, Escherichia coli, β-hemolytic streptococcus A, hepatitis A antigen, Hbs antigen and influenza virus, influenza hemagglutination Bacteria consisting of elemental peptides /
Protein A as well as antibodies against the virus mixture
The adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 10, further comprising an antibody against the antigen, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 12. The biocoat according to claim 1, further comprising an antibody against a hepatitis A antigen and an antibody against a viral capsid, wherein the biocoat is coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in columnar biosystems. 13. An antibody against hepatitis B antigen (Hbs) or a nuclear fragment (DNA) of hepatitis B antigen (Hbs) and an antibody against a viral capsid, coated with a monoclonal or polyclonal antibody against the above-mentioned antigen. An adsorbent for use in the biocoated columnar biosystem according to any one of claims 1 to 12. 14. The method according to claim 1, further comprising an antibody against hepatitis B antigen (Hbs) and an antibody against transactivator Hbx protein, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the biocoated column-shaped biosystem according to the above item. 15. The biocoated column according to claim 1, further comprising an antibody against the hepatitis C virus genome (nucleocapsid protein), coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used for biosystems. 16. The method of claim 16, further comprising an antibody against reverse transcriptase and an antibody against hepatitis C antigen, protein A, herpes simplex, influenza and influenza hemagglutinin peptides, coated with a monoclonal or polyclonal antibody against said antigen. Items 1 to 1
5. An adsorbent used in the biocoated columnar biosystem according to any one of the items 5. 17. A β-hemolytic streptococcus A, endothelin (VEGF), endothelin fragment (VEGF fragment),
Endothelin-receptor-antagonist (VEGF
-Receptor-antagonists), antibodies to VCAM, protein A, conductin protein, SDF-1-protein, 6-C-kine-protein and MIP-3β-protein, further coated with monoclonal or polyclonal antibodies against said antigens An adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 16. 18. A β-hemolytic streptococcus, protein A, P
The adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 17, further comprising an antibody against glycoprotein and lipid, and coated with a monoclonal or polyclonal antibody against the antigen. . 19. HLA-DR 1,2,4, endothelin (VEGF), a fragment of endothelin (VEGF fragment), an endothelin-receptor-antagonist (V
EGF-receptor-antagonist), VCAM, protein A, conductin protein, SDF-1-protein, 6-C-kine-protein and MIP-3
19. The adsorbent used in a biocoated columnar biosystem according to any one of claims 1 to 18, further comprising an antibody against β-protein, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 20. An antibody against HLA-DR 1,2,4, an antibody against viral capsid, and an antibody against oligodendrocyte glycoprotein Typ (MOG), coated with a monoclonal or polyclonal antibody against the above-mentioned antigen. An adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 19. 21. An antibody against HLA-DR 1,2,4, an antibody against oligodendrocyte glycoprotein (MOG), and an antibody against Epstein-Barr virus (EBV). The adsorbent for use in a biocoated columnar biosystem according to any one of claims 1 to 20, which is coated with a polyclonal antibody. 22. The biocoat according to any one of claims 1 to 21, further comprising an antibody against acetylcholine, or an antibody against acetyl receptor or a fragment thereof, wherein the biocoat is coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in a columnar biosystem. 23. The biocoated according to any one of claims 1 to 22, further comprising an antibody to immunogenetic thyroiditis and acetylcholine, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for columnar biosystems. 24. The method according to claim 1, further comprising an antibody against β-hemolytic streptococcus, influenza virus, influenza hemagglutinin peptide and lipopolysaccharide (LPS), and an antibody against chaperonin, coated with a monoclonal or polyclonal antibody against the aforementioned antigen. Item 1
24. An adsorbent used in the biocoated column-shaped biosystem according to any one of claims 23 to 23. 25. An antibody against β-hemolytic streptococci, fan-glycopeptide, influenza virus, influenza hemagglutinin peptide, and an antibody against lipopolysaccharide against matrix-protein and β-2-microglobulin, as described above. 25. The adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 24, which is coated with a monoclonal or polyclonal antibody against an antigen. 26. The biocoated columnar biomass according to any one of claims 1 to 25, further comprising an antibody against creatinine, urine, uric acid and lipid, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used in the system. 27. The biocoated according to any one of claims 1 to 26, further comprising an antibody against Coxsackie virus, viral capsid and van-glycoprotein, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used in columnar biosystems. 28. The method of claim 19, further comprising an antibody to herpes simplex, influenza virus, influenza hemagglutinin peptide, giant cell virus, protein A, and fan-glycoprotein to lipids, coated with a monoclonal or polyclonal antibody to said antigen. 28. An adsorbent used in the biocoated columnar biosystem according to any one of 1 to 27. 29. CD20B cell-lymphocyte, epithelial specific antigen (ESA), anti-human episialin (EMA),
Farnesyl-transferase, cyclin dependent kinase, E1-A-protein, ATM, MLH-1,
XP-A, XP-B, MGMT, BLM, NF1, PT
29. The biocoated columnar biomass according to any one of claims 1 to 28, further comprising an antibody against H, p27, RB and an antibody against caspase activator, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used in the system. 30. An antibody against human reverse transcriptase and CD
An antibody against 20B cell lymphocytes, further coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the biocoated column-shaped biosystem according to the above item. 31. The biocoated columnar biosystem according to any one of claims 1 to 30, further comprising an antibody against CD5 and CD72B cell lymphocytes, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for. 32. an antibody against human reverse transcriptase,
d5, an antibody against CD72 of B cell lymphocytes, epithelial specific antigen (ESA), anti-human episialin (EM
A), farnesyl-transferase, cyclin-dependent kinase, E1-A-protein, ATM, MLH
-1, XP-A, XP-B, MGMT, BLM, NF
32. The biocoated column according to any one of claims 1 to 31, further comprising an antibody against PTH, p27, RB, and an antibody against caspase activator, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used for biosystems. 33. The biocoated according to any one of claims 1 to 32, further comprising an antibody against CD2, CD3 and CD20 of B cell lymphocytes, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for columnar biosystems. 34. An antibody against human reverse transcriptase and CD
34. The biocoated according to any one of claims 1 to 33, comprising an antibody against CD3, CD5, CD7 and an antibody against T lymphocytes, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for columnar biosystems. 35. Monoclonal C against T lymphocytes
Antibodies to D2, CD3, CD5 and CD7, epithelial specific antigen (ESA), anti-human episialin (EM
A), farnesyl-transferase, cyclin-dependent kinase, E1-A-protein, ATM, MLH
-1, XP-A, XP-B, MGMT, BLM, NF
35. The biocoated column according to any one of claims 1 to 34, comprising an antibody against 1, PTH, p27, RB and an antibody against caspase activator, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used in biosystems. 36. An antibody against human reverse transcriptase, an antibody against CD2, CD3, CD5 and CD7 of T lymphocytes, and an antibody against epithelial specific antigen (ESA). An adsorbent for use in a biocoated columnar biosystem according to any one of claims 1 to 35. 37. CD13 and CD1 of myeloid leukemia cells
37. The biocoated columnar biosystem according to any one of claims 1 to 36, further comprising an antibody against CD15, CD33, and CD34, which is coated with a monoclonal or polyclonal antibody against the antigen. Sorbent. 38. An antibody against human reverse transcriptase and CD13, CD14, CD15, CD3 of myeloid leukemia cells.
3, CD34, epithelial specific antigen (ESA), anti-human episialin (EMA), farnesyl-transferase, cyclin dependent kinase, E1-A-protein, ATM, MLH-1, XP-A, XP-B, MGM
38. The biocoat according to any one of claims 1 to 37, further comprising an antibody against T, BLM, NF1, PTH, p27, RB, and an antibody against caspase, coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in a columnar biosystem. 39. An antibody against human reverse transcriptase and HL
39. The biocoated columnar biosystem according to any one of claims 1 to 38, further comprising an antibody against A-DR, HLAB3503, and CD34 antibodies, coated with a monoclonal or polyclonal antibody against the antigen. Adsorbent. 40. Human reverse transcriptase, C of T cell lymphocytes
40. The biocoated columnar biosystem according to any one of claims 1 to 39, comprising an antibody against D5 and an antibody against epithelial specific antigen (ESA), coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for. 41. An antibody against human reverse transcriptase and PG
41. An antibody against M3 promyelocytic cells (Moab) and an antibody against retonoid acid-receptor alpha, further coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the biocoated column-shaped biosystem according to any one of the above. 42. An antibody against human reverse transcriptase and Ma
b-Antibodies against macrophages and epithelial specific antigen (ES
A), anti-human episialin (EMA), farnesyl-transferase, cyclin-dependent kinase, E
1-A-protein, ATM, MLH-1, XP-A,
XP-B, MGMT, BLM, NF1, PTH, p2
7. The method according to claim 1, further comprising an antibody against RB and an antibody against caspase, coated with a monoclonal or polyclonal antibody against the antigen.
The adsorbent used in the biocoated column-shaped biosystem according to any one of the first to third aspects. 43. An antibody against human reverse transcriptase, protein A, conductin protein, SDF-1-protein, 6-kine-protein, MIP-3β-protein, and an antibody against VCAM. 43. The adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 42, which is coated with a monoclonal or polyclonal antibody. 44. The method of claim 1, further comprising an antibody against reverse transcriptase, P-glycoprotein (MDR) and a P-glycoprotein (MDR) fragment, coated with a monoclonal or polyclonal antibody against the antigen. An adsorbent for use in the biocoated column-shaped biosystem according to any one of the preceding claims. 45. Reverse transcriptase, vascular-endothelial growth factor (V
5. An antibody against EGF), a fragment of vascular-endothelial growth factor (VEGF) and a VEGF-receptor-antagonist, coated with a monoclonal or polyclonal antibody against said antigen.
5. An adsorbent used in the biocoated columnar biosystem according to any one of 4. 46. An antibody against epithelial specific antigen (ESA) and matrix metalloproteinase-2 (MMP-
2. An antibody against 2) and / or against an activator of matrix metalloproteinase-1 (MT1-MMP), coated with a monoclonal or polyclonal antibody against said antigen.
46. The adsorbent used in the biocoated columnar biosystem according to any one of the above items 45 to 45. 47. Antibodies to oligodeoxynucleotides used in antisense therapy or from gene therapy, from gene replacement therapy, from gene transfer therapy, from viral vector gene therapy, from viral vector augmentation therapy. DNA from artificial chromosome therapy
Tumor suppressors from plasmids, from immunogenetic therapy-
47. An antibody according to any one of claims 1 to 46 further comprising an oncogene-an antibody from apoptosis-therapy, against antisense from recombinant therapy, coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 48. A monoclonal antibody against said antigen, further comprising an antibody against reverse transcriptase, P-glycoprotein, an antibody against HER2 / neoprotein, an antibody against anti-human episialin (EMA), and an antibody against VCAM. 48. The adsorbent used in the bio-coated columnar biosystem according to any one of claims 1 to 47, which is coated with a polyclonal antibody. 49. Reverse transcriptase, protein HER-2 /
New protein, MYC, ERBB1-3, RAS, MS
Further comprising antibodies to H2, p53 and VCAM;
49. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 48, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 50. An antibody against reverse transcriptase and HER-
2 / new protein, MYC, ERBB1-3, RAS,
Antibodies to muteins arising from cancer growth, such as MSH2, p53 and VCAM.
50. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 49, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 51. An antibody against reverse transcriptase, RAS,
Antibodies to muteins arising from cancer growth, such as MSH2, p53 and VCAM.
The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 50, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 52. Antibodies to vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists, matrix proteins, antibodies to catenin (α, β) and neuronal adhesion proteins and cadherins 53. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 51, further comprising an antibody against the antigen, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 53. An antibody against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF), a VEGF-receptor antagonist, VCAM and HL
53. An antibody against A and an antibody against human leukocytes, further coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 54. An antibody against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF), a VEGF-receptor-antagonist, VCAM, and HLA.
54. The bio-engine according to any one of claims 1 to 53, further comprising an antibody against and / or an antibody against human leukocytes and / or T lymphocytes, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used in coated columnar biosystems. 55. An antibody against the VCAM protein,
55. The biopsy according to any one of claims 1 to 54, further comprising an antibody against the receptor for the glycate product, and / or an antibody against hemozoin, coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in coated columnar biosystems. 56. An antibody against a soluble form of the endoplasmic reticulum falciparum antigen, an antibody against the VCAM protein,
56. The bio-coated columnar biomass of any one of claims 1 to 55, further comprising an antibody to the glycate product receptor and an antibody to hemozoin, coated with a monoclonal or polyclonal antibody against the antigen. Adsorbent used in the system. 57. A monoclonal or polyclonal antibody against said antigen, further comprising an antibody against the soluble form of the plasmaplasmic falciparum antigen, an antibody against the VCAM and ICAM proteins, an antibody against the glycate product receptor, and an antibody against hemozoin. The adsorbent used in the bio-coated columnar biosystem according to any one of claims 1 to 56, which is coated with: 58. An antibody to a soluble form of the plasmaplasmic falciparum antigen or a glycosylphosphatidyl-inositol product (GP) from plasmaplasmic falciparum, trypanosome brucei or Mexican leishmania
58. The antibody of claim 1 to 57, further comprising an antibody to I), or to VCAM and ICAM proteins, to glycate product receptor, or to hemozoin, and coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 59. An antibody against a soluble form of the plasmaplasmic falciparum antigen or a glycosylphosphatidyl-inositol product (GP) from the plasmaplasmic falciparum, trypanosome brucei or Mexican leishmania
I) or an antibody against the VCAM and ICAM proteins, an antibody against the glycate product receptor, or an antibody against hemozoin, and an antibody against lipopolysaccharide, and coated with a monoclonal or polyclonal antibody against the above-mentioned antigen. An adsorbent for use in the bio-coated columnar biosystem according to any one of claims 1 to 58. 60. The method according to any one of claims 1 to 59, further comprising an antibody against hemozoin and an antibody against endothelial receptor type PECAM-1 / CD31, wherein the antibody is coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in biocoated columnar biosystems. 61. The bio-coated according to any one of claims 1 to 60, further comprising an antibody against Mycobacterium leprae, Mitsuda antigen, Damendula antigen, and coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for columnar biosystems. 62. The method according to any one of claims 1 to 61, further comprising an antibody against VCAM and ICAM proteins, as well as an antibody against Mycobacterium leprae, Mitsuda antigen and Damendula antigen, coated with a monoclonal or polyclonal antibody against the antigen. An adsorbent for use in the bio-coated columnar biosystem according to claim 1. 63. Protein A, protein p59Fyn
63. An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 62, further comprising an antibody against the kinase, coated with a monoclonal or polyclonal antibody against said antigen. 64. Human reverse transcriptase, protein A, protein p59Fyn, activator protein-1 (A
64. The adsorbent used in the biocoated columnar biosystem according to any one of claims 1 to 63, further comprising an antibody against P-1), wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. . 65. Human reverse transcriptase, protein A, protein p59Fyn, activator protein-1 (A
65. The biocoat according to any one of claims 1 to 64, further comprising an antibody against P-1) and an antibody against serum amyloid A protein (SAA), wherein the biocoat is coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in a columnar biosystem. 66. Human reverse transcriptase, protein A, protein p59Fyn, activator protein-1 (A
P-1) and antibodies to serum amyloid A protein (SAA), plasminogen-activator-inhibitor-type-1 antigen (PAI-1), as well as farnesyl-transferase, cyclin-dependent kinase and caspase activator. 66. The adsorbent used in a bio-coated columnar biosystem according to any one of claims 1 to 65, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 67. A human reverse transcriptase, protein-1 (A
P-1), serum β-amyloid protein, fragment of β-amyloid protein, β-amyloid precursor protein (βAPP), oncostatin M protein (OS
67. An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 66, comprising an antibody against M), wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 68. An antibody against human reverse transcriptase, a mutated p53 protein; 68. The antibody of any one of claims 1 to 67, further comprising an antibody to farnesyl-transferase, a cyclin dependent kinase and a caspase activator, as well as an antibody to the 67 antigen, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used for bio-coated columnar biosystems. 69. A monoclonal antibody against the antigen, further comprising an antibody against human reverse transcriptase, a mutant p53 protein, and an antibody against a protein induced by using cholesterol-liposome gene transferred to a tumor. 69. The adsorbent used in the bio-coated columnar biosystem according to any one of claims 1 to 68, which is coated with a polyclonal antibody. 70. Antibodies to conductin and P-selectin as well as reverse transcriptase, mutant p53 protein, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists. 70. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 69, wherein the adsorbent is comprised of a monoclonal or polyclonal antibody against the antigen. 71. Human reverse transcriptase, β-2 microglobulin (B2-MG), vascular endothelial growth factor (VEGF),
Claims further include antibodies to monoclonal farnesyl-transferase, cyclin-dependent kinase and caspase activator, as well as fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, coated with monoclonal or polyclonal antibodies to the aforementioned antigens Items 1 to 70
An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 72. β-2 microglobulin (B2-M
G) vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, as well as monoclonal farnesyl-
72. Any one of claims 1 to 71 further comprising antibodies to transferase, cyclin dependent kinase and caspase activator, coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 73. An antigen as described above, further comprising an antibody to vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, and an antibody to oncostatin-protein and interleukin-6. 8. Coated with a monoclonal or polyclonal antibody against
3. An adsorbent for use in the bio-coated columnar biosystem according to any one of 2. 74. Human reverse transcriptase, receptor antigen CD
74. The bio-coated columnar biosystem according to any one of claims 1 to 73, further comprising an antibody against p4 antigen and an antibody against the p24 antigen, wherein the column is coated with a monoclonal or polyclonal antibody against the antigen. Adsorbent. 75. The method of claims 1 to 74, further comprising an antibody against human reverse transcriptase, a monoclonal receptor antigen CD4, and an antibody against HIV-protease inhibitor, coated with a monoclonal or polyclonal antibody against said antigen. Any one
An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 76. The bio-coated according to any one of claims 1 to 75, further comprising an antibody against Mycobacterium, Mycobacterium tuberculosis, BCG antigen, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for columnar biosystems. 77. The method of claim 1, further comprising an antibody against M. tuberculosis and a BCG antigen, coated with a monoclonal or polyclonal antibody against said antigen.
78. The adsorbent used in the bio-coated columnar biosystem according to any one of Items 76 to 76. 78. Mycobacterium tuberculosis, BCG antigen, vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
And antibodies to VEGF-receptor-antagonists, antibodies to VCAM, and antibodies to farnesyl-transferase, cyclin-dependent kinase and caspase activator as well as telomerase, coated with monoclonal or polyclonal antibodies against said antigens. An adsorbent used in the bio-coated columnar biosystem according to any one of claims 1 to 77. 79. An antibody against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, VCAM, HLA, an antibody against human leukocytes, T lymphocytes, and an antibody against P-selectin 79. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 78, further comprising an antibody, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 80. An antibody against HLA, an antibody against human leukocytes, an antibody against T-lymphocytes, extracellular matrix, and an antibody against P-selectin, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent for use in the bio-coated columnar biosystem according to any one of claims 1 to 79. 81. Eosinophil cationic protein (EC
81. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 80, further comprising an antibody to P), wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 82. An antibody against human reverse transcriptase, an antibody against mutated p53 protein,
An antibody against a bar virus and an E1A virus protein, further coated with a monoclonal or polyclonal antibody against said antigen.
90. The adsorbent used in the bio-coated columnar biosystem according to any one of Items 81 to 81. 83. An antibody against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, VCAM, and an antibody against HLA-B-7 residue 75-84 of the alpha domain. 83. The bio-coated according to any one of claims 1 to 82, further comprising an antibody against human leukocytes and an antibody against T lymphocytes and P-selectin, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used in columnar biosystems. 84. An antibody against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, VCAM, and an antibody against HLA-B-7 residue 75-84 of the alpha domain. 84. The adsorbent used in a bio-coated columnar biosystem according to any one of claims 1 to 83, further comprising a monoclonal or polyclonal antibody against the antigen. 85. An antibody against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, VCAM, and A-
84. The bio-coated columnar biosystem according to any one of claims 1 to 84, comprising an antibody against β-2-M-amyloid, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent. 86. Vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, VCAM and A-β-2-M-
Amyloid, Conductin-protein, SDF-1-
Protein, 6-C-kine-protein and MI
86. The bio-coated columnar biosystem according to any one of claims 1 to 85, further comprising an antibody against the P-3-β-protein, wherein the column is coated with a monoclonal or polyclonal antibody against the antigen. Adsorbent. 87. An antibody against A-β-2-M-amyloid-selectin (P, L), CD994, NKG2ABCL2, vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and VEGF-receptor 87. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 86, further comprising an antibody against the antagonist, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 88. The bio-coated, columnar biosystem according to any one of claims 1 to 87, further comprising an antibody against ammonia bile acid and bilirubin, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for. 89. CD3, LAF, A-β-2-M-amyloid-selectin (P, L), CD994, NKG
90. The method of claims 1 to 88, further comprising an antibody against 2ABCL2, vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor antagonist, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent for use in the bio-coated columnar biosystem according to any one of the preceding claims. 90. Antibodies to CD994, NKG2A, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists, coated with monoclonal or polyclonal antibodies against the aforementioned antigens 90. An adsorbent for use in the bio-coated columnar biosystem according to any one of claims 1 to 89. 91. The bio-coated column according to any one of claims 1 to 90, further comprising an antibody against CD3 and LAF-1-α, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used in biosystems. 92. MDR-1-protein type MRK
16 and C219, further comprising antibodies against vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists, protein A and P-selectin, coated with monoclonal or polyclonal antibodies against the aforementioned antigens An adsorbent for use in a biocoated columnar biosystem according to any one of claims 1 to 91. 93. MDR-1-protein type MRK
16 and C219, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor antagonists, vascular endothelial growth factor (VEGF)
F) Fragments of vascular endothelial growth factor (VEGF) and VEG
93. The bio-coated columnar biosystem according to any one of claims 1 to 92, further comprising an antibody against an F-receptor-antagonist protein, coated with a monoclonal or polyclonal antibody against said antigen. Sorbent. 94. An antibody against a fusion protein comprising a Fab fragment from a monoclonal antibody (C215) and SEA (Staphylococcal enterotoxin antigen), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
The fragment of claim 1 and an antibody against a VEGF-receptor-antagonist, wherein the bio-coated columnar biosystem according to any one of claims 1 to 93, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used. 95. An antibody against vascular endothelial growth factor (VEGF), a fragment of vascular endothelial growth factor (VEGF) and a VEGF-receptor-antagonist, and farnesyl-
95. The biopsy according to any one of claims 1 to 94, further comprising an antibody against transferase, cyclin-dependent kinase and caspase activator and selectin (P, L), coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in coated columnar biosystems. 96. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEG)
F) Fragments and VEGF-receptor-antagonists, vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonist proteins, antibodies to selectin (P, L) and to interleukin-6 97. The bio-coated columnar biosystem according to any one of claims 1 to 95, further comprising an antibody, or an antibody to an interleukin gene expression construct, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for. 97. Epidermal cell growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
F) fragment and VEGF-receptor-antagonist, vascular endothelial growth factor (VEGF), fragment of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonist protein, selectin (P,
97. An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 96, further comprising an antibody to L) and OX40, wherein the adsorbent is coated with a monoclonal or polyclonal antibody to the antigen. . 98. The biocoat according to any one of claims 1 to 97, further comprising an antibody against HLAB3503 or a fragment or superantigen, or a receptor thereof, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used in a columnar biosystem. 99. The biopsy of any one of claims 1 to 98, further comprising an antibody to interleukin 8 or a fragment or superantigen, or a receptor thereof, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used in overcoated column-shaped biosystems. 100. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and antibodies to VEGF-receptor-antagonists, selectin (P, L) and interleukin-1 further coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 101. Epidermal cell growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
Claims 1 to 100 further comprising a fragment of GF) and an antibody to the VEGF-receptor antagonist, selectin (P, L) and an antibody to the interleukin-2 receptor, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 102. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and VEGF-receptor-antagonists, selectin (P, L) and squamous cell carcinoma-antigen (SC
The adsorbent used in the bio-coated columnar biosystem according to any one of claims 1 to 101, further comprising an antibody to C), wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 103. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
(GF) and antibodies to VEGF-receptor-antagonists, selectin (P, L) and matrix-protein-tenascin-C (TN-C), coated with monoclonal or polyclonal antibodies against said antigens. 113. An adsorbent used in the bio-coated columnar biosystem according to any one of 1 to 102. 104. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and a VEGF-receptor-antagonist, an antibody against selectin (P, L) and an antibody against sialyl Lewis x, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent for use in the bio-coated columnar biosystem according to claim 1. 105. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE)
A fragment of GF) and an antibody against VEGF-receptor-antagonist, selectin (P, L), and an antibody against IGM-cytostatic compound, coated with monoclonal or polyclonal antibody against said antigen. Any one of 104
An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 106. An antibody against protein A, an antibody against human HLA class I antigen, an antibody against antithrombopoietin, liposaccharide, and an antibody against fanglycoprotein, further coated with a monoclonal or polyclonal antibody against the aforementioned antigen. An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 105. 107. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and antibodies to VEGF-receptor-antagonists, selectin (P, L) and NF-kapp-B-gene expression constructs, coated with monoclonal or polyclonal antibodies against said antigens. 107. An adsorbent for use in a bio-coated columnar biosystem according to any one of 106. 108. An epidermal growth factor (EGFR), a vascular endothelial growth factor (VEGF), a vascular endothelial growth factor (VE
GF) and antibodies to VEGF-receptor antagonists, selectin (P, L) and endothelial activating polypeptide II (EMAPII), further coated with monoclonal or polyclonal antibodies against said antigens. An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 109. An epidermal growth factor (EGFR), a vascular endothelial growth factor (VEGF), a vascular endothelial growth factor (VE)
GF) and an antibody against VEGF-receptor antagonist, selectin (P, L), and an antibody against anti-endothelial activating polypeptide II (EMAPII), coated with monoclonal or polyclonal antibodies against the above-mentioned antigens An adsorbent for use in the bio-coated columnar biosystem according to any one of claims 1 to 108. 110. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
(GF) and VEGF-receptor-antagonist, selectin (P, L), anti-CD3 and an antibody against glycoprotein EGP2 as a bispecific antibody, coated with a monoclonal or polyclonal antibody against said antigen. 110. An adsorbent used in the bio-coated columnar biosystem according to any one of items 1 to 109. 111. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE)
GF) and VEGF-receptor-antagonist, selectin (P, L), macrophage-migration-inhibitor (MIF) and its antibody (anti-MI
F), Protein A, Conductin-protein, SD
111. The method according to any one of claims 1 to 110, further comprising an antibody against F-1-protein, 6-C-kine-protein and MIP-3-beta, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used in biocoated columnar biosystems. 112. Epidermal cell growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE)
(GF) and VEGF-receptor-antagonists, antibodies to selectin (P, L), and antibodies to leukemia inhibitory factor (LIF) and its antibodies (anti-LIF). An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 111, coated with: 113. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE)
113. An antibody against a fragment of GF) and a VEGF-receptor antagonist, selectin (P, L), and an antibody against an anti-lamp gene construct, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 114. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and VEGF-receptor-antagonists, selectins (P, L), substance P (SP) and antibodies to substance P fragments thereof,
114. An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 113, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 115. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and VEGF-receptor-antagonists, selectin (P, L) and interleukin-1-
115. The adsorbent used in a bio-coated columnar biosystem according to any one of claims 1 to 114, further comprising an antibody against a receptor, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against the antigen. 116. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) further comprising an antibody against VEGF-receptor-antagonist, selectin (P, L), interleukin-2 and interleukin-4, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent for use in the bio-coated columnar biosystem according to any one of the preceding claims. 117. Epidermal cell growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE)
GF) and VEGF-receptor-antagonists, selectin (P, L), substance P (SP) and vasoactive intestinal peptide (VIP), protein A,
Conductin-protein, SDF-1-protein,
2. The method of claim 1, further comprising an antibody against 6-C-kine-protein, MIP-3-β, coated with a monoclonal or polyclonal antibody against said antigen.
116. The adsorbent used in the bio-coated columnar biosystem according to any one of the above items. 118. An epidermal growth factor (EGFR), a selectin (P, L), a vascular endothelial growth factor (VEGF),
118. The method of claims 1-117, further comprising fragments of vascular endothelial growth factor (VEGF) and antibodies to VEGF-receptor-antagonists, farnesyl-transferase, cyclin-dependent kinases and prorelations, coated with monoclonal or polyclonal antibodies against said antigens. An adsorbent for use in the bio-coated columnar biosystem according to any one of the preceding claims. 119. Antibody against reverse transcriptase and the protein Her-2 / new, MYC, E
Antibodies to RBB1-3, RAS, p53 and VCA
M and antibodies to epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor-antagonists. 118. An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 118, wherein the adsorbent is comprised of a monoclonal or polyclonal antibody against the antigen. 120. An antibody against p-glycoprotein and a fragment of p-glycoprotein, an antibody against endorphin, encephalin, MSH, opioid, substance P, and an antibody against their peptides, receptor antagonists and antagonists, as described above. 120. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 119, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against an antigen. 121. An antibody against CD4, MHCII (major histocompatibility complex) -peptide complex, and LFA
And an antibody against -1 (an antigen associated with leukocyte function), coated with a monoclonal or polyclonal antibody against said antigen.
0. The adsorbent used in the bio-coated columnar biosystem according to any one of 0. 122. An antibody against the soluble form of the plasmaplasmic falciparum antigen and an antibody against the VACM-protein and / or a receptor for the glycate-product, and / or an antibody against cp26 and cp29, a circumsporozoite of the plasmaplasmic falciparum. 122. The bio-coated columnar biosystem according to any one of claims 1 to 121, further comprising an antibody against a protein and / or an antibody against hemizin, coated with a monoclonal or polyclonal antibody against said antigen. Adsorbent used for. 123. Epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE)
GF) and VEGF-receptor-antagonist, selectin (P, L), endothelial activating polypeptide II
(EMAPII), further comprising an antibody against protein A, conductin-protein, SDF-1-protein, 6-C-kine-protein and MIP-3β, coated with a monoclonal or polyclonal antibody against said antigen. 122. An adsorbent for use in a bio-coated columnar biosystem according to any one of 122. 124. The method of claim 1, further comprising an antibody against CD4 and an antibody against MHCII (major histocompatibility complex) -peptide complex, coated with a monoclonal or polyclonal antibody against said antigen.
123. The adsorbent used in the bio-coated columnar biosystem according to any one of Items 123 to 123. 125. The method of claim 1, further comprising an antibody against CD8 and an antibody against MHCII (major histocompatibility complex) -peptide complex, coated with a monoclonal or polyclonal antibody against said antigen.
125. The adsorbent used in the bio-coated column-shaped biosystem according to any one of Items 124 to 124. 126. An epidermal growth factor (EGFR), a vascular endothelial growth factor (VEGF), a vascular endothelial growth factor (VE
GF) and a VEGF-receptor-antagonist, selectin (P, L), further comprising an antibody to neuropilin as a specific inhibitor of neovascularization and endothelial proliferation, coated with a monoclonal or polyclonal antibody against the aforementioned antigen Claims 1 to 125
An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 127. An antibody against HLA-Dr1,2,4, an antibody against oligodendrocyte glycoprotein, and an antibody against semaphorin as a monoclonal type (MOG) antibody, wherein the monoclonal antibody against said antigen is 127. An adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 126 coated with a polyclonal antibody. 128. The method according to claim 1, further comprising an antibody against HLA-Dr1,2,4, an antibody against oligodendrocyte glycoprotein (MOG), an antibody against Epstein-Barr virus, and an antibody against semaphorin-protein. 127. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 127, coated with a monoclonal or polyclonal antibody against the antigen. 129. Antibody against reverse transcriptase and protein Her-2 / new, BRCA by cancer growth mutation
1, for BRCA2, RAS, MSH2, p53,
Farnesyl-transferase, cyclin dependent kinase and / or VCAM, monoclonal epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF),
130. Any of the preceding claims further comprising a fragment of vascular endothelial growth factor (VEGF) and an antibody to VEGF-receptor antagonist, selectin (P, L), coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated columnar biosystem according to claim 1. 130. Antibody against reverse transcriptase and cancer growth blocking factor Her-2 / new, BRCA1, BRC
A2, RAS, MSH2, p53, farnesyl-transferase, cyclin dependent kinase and / or V
CAM, monoclonal epidermal growth factor (EGF
R), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and antibodies to VEGF-receptor-antagonists, selectins (P, L), coated with monoclonal or polyclonal antibodies to the antigens described above. Claims 1 to 12
10. An adsorbent for use in the bio-coated columnar biosystem according to any one of 9. 131. Antibody against reverse transcriptase and oncoprotein Her-2 / new, BRCA1, BRCA2, RA
S, MSH2, p53, farnesyl-transferase, cyclin dependent kinase and / or VCAM, monoclonal epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF)
131. The bio-coat according to any one of claims 1 to 130, further comprising a fragment of and a VEGF-receptor-antagonist, an antibody against selectin (P, L), coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used in a columnar biosystem. 132. Epidermal cell growth factor (EGFR), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VE
GF) and VEGF-receptor-antagonist, selectin (P, L), endothelial activating polypeptide II
(EMAPII), Conductin-protein, SDF-
2. The method according to claim 1, further comprising antibodies against 1-protein and 6-C-kine-protein, coated with monoclonal or polyclonal antibodies against said antigen.
131. The adsorbent used in the bio-coated columnar biosystem according to any one of Items 131 to 131. 133. Antibody against reverse transcriptase and protein Her-2 / new, BRCA by cancer growth mutation
1, BRCA2, RAS, MSH-2, p53, farnesyl-transferase, cyclin dependent kinase and / or VCAM, epidermal growth factor (EGFR),
Selectin (P, L), vascular endothelial growth factor (VEG)
F) Fragments of vascular endothelial growth factor (VEGF) and VEG
F-receptor-antagonist, monoclonal E1
133. An antibody according to any of claims 1 to 132, further comprising an antibody against -A-protein, coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 134. An antibody against CD4 and CD8 and M
Further comprising an antibody against HCII (major histocompatibility complex) -peptide complex, MHCII (major histocompatibility complex) -peptide complex-I-peptide complex, and an antibody against peptidyl caspase inhibitor. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 133, wherein the adsorbent is coated with a monoclonal or polyclonal antibody against an antigen. 135. An antibody against reverse transcriptase and a protein Her-2 / new, BRCA by cancer growth mutation
1, BRCA2, RAS, MSH, p53, farnesyl-transferase, cyclin dependent kinase and
And / or VCAM, monoclonal epidermal growth factor (E
GFR), vascular endothelial growth factor (VEGF), fragments of vascular endothelial growth factor (VEGF) and VEGF-receptor
135. Any one of claims 1 to 134, further comprising an antibody to an antagonist, selectin (P, L), E1-A-protein and an antibody to a monoclonal caspase activator, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 136. An antibody against HLA-DR1,2,4, an antibody against oligodendrocyte glycoprotein (MOG), an Epstein-Barr virus (EBV),
Claims 1 to 135 further comprising an antibody against the polypeptide neurotoxin and an antibody against the semaphorin protein as a monoclonal antibody, coated with a monoclonal or polyclonal antibody against said antigen.
An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 137. An antibody against HLA-DR1,2,4, an antibody against oligodendrocyte glycoprotein (MOG), an antibody against Epstein-Barr virus (EBV), and a microtubulin-related protein (MAP).
e) an antibody against MAPs, tau-protein and an antibody against semaphorin protein as a monoclonal antibody, wherein the antibody is coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated columnar biosystem according to claim 1. 138. An antibody against CD4 and MHCII
A monoclonal or polyclonal antibody against said antigen, further comprising an antibody against (major histocompatibility complex) -peptide complex, an antibody against LFA-1 (leukocyte function-related protein) and an antibody against HIV-proteinase-inhibitor The adsorbent for use in the bio-coated columnar biosystem according to any one of claims 1 to 137, wherein the adsorbent is coated with: 139. An antibody against CD4, MHCII (major histocompatibility complex) -peptide complex, and LFA
-1 (leukocyte function-related protein) and H
2. The method of claim 1, further comprising an antibody against an IV-proteinase inhibitor and an antibody against an integrin, a viral capsid, or a glycopeptide, coated with a monoclonal or polyclonal antibody against said antigen.
138. The adsorbent used in the bio-coated columnar biosystem according to any one of items 138 to 138. 140. An antibody against CD4, MHCII (major histocompatibility complex) -peptide complex, and LFA
139 (leukocyte function-related protein), an antibody against an HIV-proteinase-inhibitor, and an antibody against an integrin, viral capsid, or glycopeptide, coated with a monoclonal or polyclonal antibody against the antigen. An adsorbent used in the bio-coated columnar biosystem according to any one of the above. 141. An antibody against reverse transcriptase and the cancer growth mutein Her-2 / new, BRCA1, BR
CA2, RAS, MSH2, p53, farnesyl-transferase, cyclin-dependent kinase and / or VCAM, epidermal growth factor (EGFR), E1-A-
Protein ATM, HLM1, XP-A, XP-B, M
141. The method according to any one of claims 1 to 140, further comprising an antibody against GMT, BLM, NF1, PTH, p27, RB and an antibody against a monoclonal caspase activator, coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in biocoated columnar biosystems. 142. The method of any one of claims 1 to 141, further comprising an antibody to creatinine, urine, uric acid and lipid, and an antibody to β-microtubulin and amyloid, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated column-shaped biosystem according to the above item. 143. The method of any of claims 1-142, further comprising an antibody to cholera toxin, pseudomonas ergotoxin A, staphylococcal alpha toxin and staphylococcal enterotoxins A and B, coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent for use in the bio-coated columnar biosystem according to any one of the preceding claims. 144. An antibody against reverse transcriptase and a cancer growth mutein Her-2 / new, epithelial specific antigen (E
SA), RAS, MSH2, p53, farnesyl-transferase, cyclin-dependent kinase and / or VCAM, epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF) ) And VEGF-receptor-antagonists, selectins, E1-A-protein ATM, MLH-1, XP-A, XP-B, MGMT,
143. The bio-engine according to any one of claims 1 to 143, further comprising an antibody against BLM, NF1, PTH, p27, RB, and an antibody against a monoclonal caspase activator, coated with a monoclonal or polyclonal antibody against the antigen. Adsorbents used in coated columnar biosystems. 145. An antibody against reverse transcriptase and a cancer growth mutein Her-2 / new, epithelial specific antigen (E
SA), RAS, MSH2, p53, farnesyl-transferase, cyclin-dependent kinase and / or VCAM, epidermal growth factor (EGFR), selectin (P, L), vascular endothelial growth factor (VEGF), vascular endothelial growth factor (VEGF) ) And VEGF-receptor-antagonists, selectins, E1-A-protein ATM, MLH-1, XP-A, XP-B, MGMT,
Antibodies to BLM, NF1, PTH, p27, RB, antibodies to monoclonal caspase activator, and matrix metalloproteinase-2 (M
145. An antibody against MP-2) and / or an antibody against matrix metalloproteinase-1 (MT1-MMP) further coated with a monoclonal or polyclonal antibody against said antigen. An adsorbent used in the bio-coated columnar biosystem according to the above. 146. An antibody against reverse transcriptase and the protein Her-2 / new, epithelial specific antigen (ESA), RA
S, MSH2, p53, farnesyl-transferase, cyclin dependent kinase and / or VCAM, epidermal growth factor (EGFR), selectin (P, L),
Vascular endothelial growth factor (VEGF), vascular endothelial growth factor (V
EGF) fragments and VEGF-receptor antagonists, selectins, E1-A-protein ATM, ML
H-1, XP-A, XP-B, MGMT, BLM, NF
1, further comprising an antibody against PTH, p27, RB and an antibody against monoclonal caspase activator, matrix metalloproteinase-2 (MMP-2) and / or matrix metalloproteinase-1 (MT1-MMP); 145. The adsorbent used in the bio-coated columnar biosystem according to any one of claims 1 to 145, wherein the adsorbent is coated with a polyclonal antibody. 147. An antibody against HLA-DR1,2,4, an antibody against oligodendrocyte glycoprotein (MOG), an antibody against a neurotrophic stimulant as well as a nerve growth inhibitor type NI35 / 250, and a semaphore. 147. The adsorbent for use in a bio-coated columnar biosystem according to any one of claims 1 to 146, further comprising an antibody against phosphorus, coated with a monoclonal or polyclonal antibody against the antigen. 148. Angiogenin, chemokin, colony stimulating factor (CSF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), insulin-like growth factor (IG
F), interferon (INF), interleukin (IL) keratinocyte growth factor (KGF), leptin (OB), leukemia inhibitory factor (LIF), nerve growth factor (NGF), oncostatin M (OSM), platelets Induced cell growth factor (PD-ECGF), pleiotropic stem cell growth (SCF), transforming growth factors a and b (TG
147. The bio-coated column according to any one of claims 1 to 147, further comprising an antibody against a growth factor such as Fa and TGF-b), coated with a monoclonal or polyclonal antibody against said antigen. Adsorbents used for biosystems. 149. Actin, cytokeratin, intermediate filament, microtubulin, cell adhesion protein,
Organelles, extracellular matrix, cell cycle effecting proteins, nuclear effecting proteins, human cell antigens of receptors, hormones, signal transducer types, growth proteins, superantigens and oncogens, as well as their precursors and metabolites And antibodies against conjugates, prions, viroids, viruses, pro and eukaryotes, helminths, bacteria, protozoaea or fragments thereof, further coated with monoclonal or polyclonal antibodies against the aforementioned antigens. 149. An adsorbent for use in the bio-coated columnar biosystem according to any one of claims 1 to 148. 150. The bio-coated article according to any one of claims 1 to 149, comprising an adsorbent material consisting of plastic, plastic coated metal, glass, cellulose, agar or agar agglomerates, sepharose or a sepharose derivative. Adsorbent used for columnar biosystems. 151. The plastic material is a polyolefin, polyester, polyether, polyimide, polyurethane, polyvinyl chloride, polystyrene, polysulfone, polyacrylate, polymethacrylate, polyvinylpyrrolidone, fluoropolymer or a derivative of the above compound, or a derivative of the above compound. 16. A mixture comprising a silicon-containing copolymer or a silicon-containing copolymer thereof.
0 adsorbent. 152. The adsorbent according to claim 151, wherein said plastic material shows polarity under a chemical reaction. 153. The adsorbent of claim 151 or 152, wherein the surface of the plastic comprises an adhesive material such as bromocyan, thiophosgene, thionyl chloride. 154. The adsorbent according to any one of claims 150 to 152, wherein the antibody is covalently bonded to or adsorbed to the surface of the material. 155. The amount of the antibody against TNF used in the coating of the adsorbent is in the range of 1 to 95% by weight, and the amount less than 100% by weight is effective against the specific pathogen of the disease to be treated. 155. The method of any of claims 150 to 154, wherein said antibody is replaced by another antibody of interest.
The adsorbent according to Item. 156. The TNF and / or anti-TNF and / or TNF fragment used for coating the adsorbent;
And / or the amount of antibody to the anti-TNF fragment is between 1 and 95
155. The method of claims 150 to 154, wherein the amount in the range of less than 100% by weight is replaced by another antibody which is effective against the specific pathogen of the disease to be treated. An adsorbent according to any one of the preceding claims. 157. The column-shaped system is as defined in any one of claims 1 to 1.
56. A columnar system for use in hemodialysis or plasma export that is effective in eliminating pathogenic antigens with the biocoated adsorbent material according to any one or more of items 56. 158. The columnar system used for hemodialysis or plasma export according to claim 157, wherein the inner surface of the columnar system includes a biocoated adsorbent. 159. The columnar system used for hemodialysis or plasma delivery according to claim 157, wherein said columnar system is packed with a biocoated adsorbent such as beads. 160. Specific pathogen, specific growth factor, specific protein or peptide, specific toxin, specific enzyme, specific hormone, specific receptor, specific cell or tissue marker, biological fluid, tissues and tissues, or monoclonal antibody 157. The adsorption according to claims 157 to 159, wherein is produced and used for the clinical use of diseases caused by specific cytokines in cell cultures from tissues whose tissues can be used to biocoat the column system. Use of a sexual columnar system. 161. A specific pathogen, a specific growth factor, a specific protein or peptide, a specific toxin, a specific enzyme, a specific hormone, a specific receptor, a specific cell or tissue marker, a biological fluid, a specific cytokine in tissues and tissues, Or cell cultures from tissues are not measurable, but other antigens, antibodies or specific factors directly or indirectly involved in the disease are sought in the blood or tissue, monoclonal antibodies are produced, the antigen and 160. Use of a column system for adsorption according to claims 157 to 159, wherein the antibody is used for clinical use in diseases where the antibody can be used to biocoat the column system. 162. The use according to claims 157 to 159 for the treatment of direct or indirect immunogenetic pathogenesis with measurable antigens and / or antibodies, wherein the antigen or monoclonal is available for the biocoating of the columnar system. Practical use of adsorbents or columnar biosystems. 163. The isolate from the biological fluid of the diseased organ is subjected to a biocoating step in a columnar system.
160. The method according to any one of claims 1 to 159, wherein the column is available for an antigen or a monoclonal antibody during packing of the column, and further comprises an additional antibody, coated with a monoclonal or polyclonal antibody against the antigen. 160. The adsorbent or columnar biosystem according to claim 157 to 159 for the treatment of a disease caused by another pathogenic agent according to claim 160 to 161 when used as an adsorbent usable for a biocoated columnar biosystem. Practical use of.